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1 Introduction 1 
1 Introduction 
1.1 Background and the Objectives of the Study 
Generic medicines are growing in importance in the industrialized countries 
simultaneously as the overall usage of medicines is increasing. In the developed 
countries, generic medicines industry is seen even more important than 
traditional innovative pharmaceutical industry. One main reason for this is the 
cost cutting benefits and savings generic substitution offers for the payers of the 
medicines. Another generally acknowledged cause for the rise of the generic 
medicines is that people live older in the industrialized countries and therefore 
the overall costs of the health care are on the rise. Generic medicines offer a way 
for governments to cut down their health expenses. Furthermore, the rising 
research and development costs in the innovative medicines industry make 
companies search revenue streams in other businesses including generic 
medicines. (DiMasi & Grabowski, 2007; European Commission, 2009; Hoffman, 
2005.)  
Generic medicines are also globally experiencing industry shaping forces from 
governments, competing industries, as well as medicine users. This puts the 
industry in an interesting position, which is even intensified by the benefits the 
industry has on the costs paid by the users and governments. Moreover, in 
Europe the reshaping of the continent and the unification of the markets 
provide even more interest for the industry-wide study. Further motivation for 
the study comes from the fact that the industry has substantial influence 
throughout Europe. A comprehensive study of the industry is needed also 
because an industry-wide study of the generic medicines has never been made. 
From all of this the main research problem of the study is formulated: “what 
kind of business environment favors generic medicines industry?” To analyze and 
answer this problem thoroughly two additional sub-problems are formulated. It 
is previously indicated that in the generic medicines industry regulation and 
coordination play an important role. These additional questions address this 
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area as well as the chosen focus of the European countries. Also the 
understanding about the other factors is needed to comprehensively 
understand the industry dynamics. The additional sub-questions are: 
1. How does the regulation and coordination influence the dynamics of the 
generic medicines industry in Europe? 
2. What other conditions are the most central for a generic medicines industry 
to succeed in Europe and how do they influence the dynamics of the industry? 
Two additional objectives are also set for this thesis. Reaching these objectives 
will help to solve previous problems and to answer the questions properly. The 
first objective of the thesis is to build a comprehensive understanding about the 
industry, its business environment, and the affecting institutional factors. This 
information about the dynamics of the industry should also be usable as a 
separate part of the thesis. The second objective is to study the differences of 
these factors between European countries and to understand the challenges and 
opportunities these differences indicate for companies and public policymakers. 
To be precise, this means that among others industry actors, demographic 
trends, and economic conditions need to be studied in addition to regulation 
and coordination.  
However, using generic medicines industry as an empirical data for 
comprehensive study is rather complex. Two main reasons for this are the 
limited number of available cases and the above described complex 
environment. For studying regulation and coordination and its effect on the 
industry, the theory of “Varieties of Capitalism” (Hall & Soskice, 2001) will be 
studied profoundly. Because generic medicines industry is highly influenced by 
the patent and promotion legislation, the understanding about these processes 
at the national level is required. Varieties of Capitalism in part assesses these. 
Moreover, Varieties of Capitalism studies have been recently pointed in the 
direction of studying more specific areas and using set theoretical methods in 
the analysis (Jackson & Deeg, 2008).  
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To produce valid study and results a rather novel methodology of fuzzy set 
qualitative comparative analysis (fsQCA) (see generally Ragin, 2000, 2008a; 
Ragin & Rihoux, 2008) is implemented in the study. FsQCA is part of emerging 
set theoretical methodologies that have been used with success in a variety of 
studies of causal complexities in social and management sciences. Methodology 
has been especially usable in studies with a relatively low number of cases and 
it fits thus into the study. A general idea of fsQCA is to combine the best aspects 
of both qualitative and quantitative research. In order to use fsQCA and build 
the configurations of different factors affecting the success of the industry deep 
substantial and theoretical understanding is needed (Ragin, 2008a).  
After building a comprehensive threefold understanding about the industry 
based on empirical evidence, the theory of Varieties of Capitalism, and the 
analysis methodology of fsQCA the analysis can be done. Concrete outcomes 
from the analysis will be the configurations of factors that lead to industry’s 
success. Comparison of these against the comprehensive understanding about 
the coordination and regulation and other affecting factors in the industry will 
provide robust and usable conclusions and recommendations. The contribution 
of the thesis includes implications for the companies involved in generic 
medicines, implications for public policies, and implications for the theories of 
fsQCA and Varieties of Capitalism. 
1.2 Scope and Limitations 
The thesis focuses on the generic medicines industry in Europe. A general 
definition of a generic medicine is that it is a medicine that is produced without 
a patent protection as original medicine’s patent has expired. Generic medicine 
is also similar to original and already authorized medicine and thus it is 
interchangeable in regard to the original medicine. Generic medicine contains 
the same quantity of active substances as original medicine. Generic medicines 
differ from original by name, appearance, and packaging. (EMEA, 2007.) The 
thesis focuses on the actors who have a marketing authorization for a generic 
medicine in Europe. Furthermore, particularly the focus is on the prescription 
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medicines. This means that among others over-the-counter (OTC) and other 
self-treatment medicines, and hospital medicines are excluded from the thesis. 
A more comprehensive industry structure will be presented in Chapter 3.1.1 
Industry Structure.  
Copied medicines are excluded from this thesis. Copied medicines differ from 
generic medicines, because copied medicines do not have a proof of 
bioequivalence to original medicine. Also excluded is the emerging industry of 
biosimilars, which are the generic versions of biomedicines.  
Geographically the study focuses on the European markets meaning the 
European Union with Switzerland, Iceland, and Norway. From these three 
additional countries, the latter two operate under the rules set by European 
Medicines Agency (EMEA) and thus have the same basic rules governing the 
generic medicines industry. Switzerland is also included in the study because of 
the similarity to the Western-European systems even though not formally being 
a member of those. The final number of countries that are included in the actual 
analysis is 24 because of the limitations in the available data. Excluded from the 
study are most notably Russia and Turkey. This is a clear choice as these 
countries clearly have different market characteristics and regulations than the 
included nations.  
1.3 Structure 
The main areas of the thesis are firstly Varieties of Capitalism as part of the 
institutional theory relating to differences in operating environments, secondly 
the dynamics and the success factors of generic medicines industry, and thirdly 
the methodology of fuzzy set qualitative comparative analysis as a part of the 
set theoretical research approaches. Because of this chosen triple theory 
approach the following structure is used. Literature review of the Varieties of 
Capitalism will be discussed in Chapter 2. Chapter 3 discusses the theory and 
empirical evidence of the generic medicines industry. Chapter 4 discusses the 
fuzzy set qualitative comparative analysis. Chapters 2, 3 and 4 together form a 
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theoretical and empirical background to the thesis. In the ending part of the 
thesis Chapter 5 illustrates data and the analysis. This chapter also finally 
bridges three previously discussed parts. Chapter 6 presents the findings and 
the results and finally Chapter 7 presents discussion and conclusions. Simplified 
visualization of the structure is presented in Figure 1 below. 
 
Figure 1: Simplified Structure of the Thesis 
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2 Literature Review: Varieties of Capitalism 
This chapter enlightens the research done so far on the management theoretical 
topic of this thesis: Varieties of Capitalism (VoC). This field of research is 
relatively new and its original work is considered being a book Varieties of 
Capitalism by Hall and Soskice (2001). This topic will be first of three parts that 
form the theoretical and empirical body of this thesis.  
2.1 Comparative Capitalisms 
The “Varieties of Capitalism” (VoC) is a relatively new framework introduced to 
the greater public by Peter A. Hall and David Soskice in their book called 
Varieties of Capitalism (2001). Theory largely builds on their previous works 
and ideas (e.g. Soskice, 1999). This term has since gathered many scholars and 
formed a new field of research. Furthermore, the legitimization of VoC literature 
has tied it to be today one of the most important parts of wider and older field of 
literature called comparative capitalisms (CC). One of the main contributions of 
CC is to explain how nations respond to economic shocks from the market 
changing forces like globalization (see Deeg & Jackson, 2007; Jackson & Deeg, 
2006). In the same context VoC focuses on market coordination. It sees firms as 
central actors in this analysis (Hall & Soskice, 2001).  
CC and VoC, depending on the definition used in literature, can be either 
synonyms or more commonly, as mentioned above, VoC can be considered the 
most recent and prominent addition to CC. One definition of CC by Deeg and 
Jackson (2007) indicates that CC field refers to the diverse set of approaches 
and frameworks that have a common concern understanding the institutional 
foundations that affect the formation of diverse business organizations within 
different nations. On the other hand, in the original form the VoC theory by Hall 
and Soskice (2001) focuses on understanding the institutional similarities and 
differences among the developed economies. Based on these definitions, the 
view that considers VoC as a part of CC is adapted to the study. Moreover, this 
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literature review focuses on VoC literature, but because of its close relativity to 
CC, some aspects are also taken from CC. 
To start from the beginning, the roots of VoC are, as stated by Hall and Soskice 
(2001, pp. 2-5), in the modernization approach (see generally Shonfield, 1965), 
neo-corporatism approach (see generally Schmitter & Lehmbruch, 1979), and in 
the social systems of production approach. Common to these approaches is that 
they focus on set of actors and have those as the main parts of the analysis. 
However, their stated level of the analysis varies. The modernization approach 
at one form analyzes states; neo-corporatism focuses on tri-partite bargaining 
that involve unions, the private sector, and government that are within one 
country; and social systems approach focuses on, for example, institutions like 
national innovation systems. As can be seen, the trend in this field has been to 
move the focus of the analysis from the nation level to the smaller and smaller 
units or sets of actors, but still keeping the focus on macro-level. VoC approach 
is first in this field that explicitly states that it tries to capture the firm at the 
center of the analysis. Firms are seen as the actors who trigger the changes in 
the institutional environment (Hall & Soskice, 2001). What are adapted then 
from the predecessors to VoC are the views on how institutions affect the 
economic performance.  
Also on the level of constructing the framework Hall and Soskice (2001) take a 
lot of influence from Michel Albert (1993) although this is not much emphasized 
in their work. Albert was the first to argue the binary division of the main 
capitalist types. He described a Rhineland type and an Anglo-Saxon type very 
much in the same way as later VoC would describe its core models. This will be 
discussed later. (Crouch, 2005; Deeg & Jackson, 2007.) 
From all the influence that have an effect on VoC literature emerge many high 
level topics, but the ones who are especially interesting for the study range from 
corporate strategy and legal systems to social policy. In addition to that, the 
actors who are analyzed in VoC approach under these topics may generally be 
individuals, firms, producer groups, or governments. From these, the thesis at 
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least partly includes all except for individuals. Furthermore, in VoC theory from 
all of these firms are seen as the main actors. This is because in capitalist 
societies firms are crucial actors and they are involved in so wide a variety of 
activities that they necessarily influence many levels of the economic 
performance. (Hall & Soskice, 2001, pp. 2-6.) 
In the original form, the main VoC framework by Hall and Soskice (2001) 
distinguishes two main ideal types of political economies, liberal market 
economies (LMEs) and coordinated market economies (CMEs). This division is 
first and foremost based on the differences observed in the developed market 
economies of Western-Europe and Northern-America. Sometimes also Japan 
and some other Organisation for Economic Co-operation and Development 
(OECD) countries are included in the analysis (e.g. Amable, 2003; Hall & 
Gingerich, 2004; Kenworthy, 2006). 
Despite the lack of analyzing all of the OECD countries, the original theory still 
categorizes all of these (Hall & Soskice, 2001, pp. 19-21). Hall and Soskice 
identify six countries to be LMEs: the USA, UK, Australia, Canada, New Zealand, 
and Ireland. Ten countries are identified as CMEs: Germany, Japan, Switzerland, 
the Netherlands, Belgium, Sweden, Norway, Denmark, Finland, and Austria. This 
leaves six of OECD countries in a more ambiguous position with having the 
elements of both of the main types. These are France, Italy, Spain, Portugal, 
Greece, and Turkey. Many studies simplify this division further by comparing 
the USA or UK as the example of ideal LME and Germany as the ideal example of 
CME (e.g. Hall & Soskice, 2001, chap. 10 Varieties of Corporate Governance: 
Comparing Germany and the UK). Generally, these countries are seen as the 
most ideal examples (e.g. Hall & Gingerich, 2004). However, this division and 
labeling can also be challenged in many various ways as will be discussed later.  
According to the theory, the main basic difference between these two ideal 
types of economies is that, in LMEs companies coordinate their activities via 
hierarchies and competitive market arrangements. In LMEs market 
relationships are characterized by the arm’s-length exchange of products or 
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services, which means that parties involved in exchange are independent and on 
an equal footing. On the other hand, in CMEs companies are more dependable 
on non-market relationships and they use these relationships more to conduct 
business and build their own competitiveness. (Hall & Soskice, 2001, pp. 8-19.) 
Hall and Soskice (2001, chap. 1 An Introduction to Varieties of Capitalism) 
classify more detailed aspects for differentiating CMEs from LMEs. They 
propose classification based on five spheres in which firms must be active in 
order to be competitive. The spheres they propose are (i) industrial relations, 
(ii) vocational training and education, (iii) corporate governance and financial 
systems, (iv) inter-firm relations, and (v) employees and internal structure. 
Institutional environment inside these spheres together differentiates CMEs and 
LMEs. 
The idea in the analysis of VoC is that the superior performance of national 
economy is dependent on situation rather than the system that is ruling. Hall 
and Soskice (2001) argue that neither of two main types of capitalisms systems, 
LMEs or CMEs, is better than the other creating good outcomes and good 
performance. To reinforce this concept, they present the idea of the institutional 
complementarities. The idea is that two institutions can be said to be 
complementary if the efficiency of one increases the efficiency of the other. This 
is similar to the concept of complementary goods. In practice, it is proposed that 
institutional practices should not be distributed randomly across nations, but 
there should be some clustering. This finally divides LMEs from CMEs as nations 
converge on complementary institutional practices. The key differences 
between LME and CME are presented in Table 1. The complementarities that 
are characteristic of the ideal types of CME and LME as proposed by Hall and 
Soskice are also presented in the table (2001, pp. 21-33).  
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Table 1: Key Differences between Ideal CME and LME in Five VoC Spheres 
 CME  
(Coordinated Market Economy) 
(Germany as an ideal example) 
LME  
(Liberal Market Economy) 
(The USA as an ideal example) 
 
Characteristic 
Implications from 
complementarities 
Characteristic 
Implications from 
complementarities 
(i) 
industrial 
relations 
Industry level 
decision 
making bodies, 
e.g. wage 
bargaining. 
Strong unions. 
Longer 
employment 
contracts.  
Relationships 
between 
individual 
worker and 
employer. 
Highly fluid labor 
markets. Easier to 
take advantage of 
new opportunities.  
(ii)  
vocational 
training and 
education 
Need for labor 
with high 
industry-
specific skills. 
Publicly subsidized 
training systems 
for industry 
specific skills. 
Need for labor 
with general 
skills that can 
be used in 
variety of 
firms. 
More in-house 
training in 
companies for 
marketable skills. 
(iii)  
corporate 
governance 
and 
financial 
system 
Not entirely 
dependent on 
public finance. 
Long run 
investments. 
Monitoring 
performance 
requires also inside 
information, which 
requires tighter 
networks.  
Public 
financing.  
Price of the stock 
important in terms 
of future financing 
and survival. 
Networks for 
information do not 
need to be so 
close.  
(iv)  
inter-firm 
relations 
Important role 
of institutions 
in facilitating 
relations.  
Collaboration 
between firms and 
universities to 
ensure technology 
transfer. 
Standard 
market 
relationships 
and 
enforceable 
contracts. 
Job rotation 
facilitates 
technology 
exchange. Inter-
firm collaboration 
not that important. 
(v)  
employee 
relations 
and internal 
structure 
Major decision 
need to be 
secured with 
multiple 
stakeholders. 
Networked 
internal structure.  
Unilateral 
decision 
making by top 
management.  
Internal structure 
not needed to 
facilitate 
networking that 
much. 
Based on this idea it is suggested that superior macroeconomic performance is a 
product of institutional coherence and therefore intermediate or not so 
institutionally coherent systems will underperform the more coherent or pure 
type LMEs or CMEs. Incoherence can occur either because of being in the middle 
in regard to coordinated and liberal market institutions or having a mix of both 
coordinated and liberal market institutions. According to Jackson and Deeg 
2 Literature Review: Varieties of Capitalism 11 
(2008) this means that there is a U-shaped relationship of economic 
performance between the countries clustered in the bipolar line of LME and 
CME. (Hall & Gingerich, 2004; Hall & Soskice, 2001; Kenworthy, 2006.)  
This central idea in VoC can be formulated as the first high level proposition for 
this thesis. A number of propositions about the issues affecting to an industry’s 
success will be formulated in this and the next chapter. Propositions in this 
chapter are more general and have possibly an effect to many industries. Next 
chapter will introduce more detailed propositions that are mostly relevant to 
the generic medicines industry.  
Proposition 1: Coherence and coordination in the economy affect the performance 
of an industry.  
By looking at Table 1 some of the complementarities and their implications can 
be observed. Key argument by Hall and Soskice (2001) is that LMEs are more 
capable of having radical innovation and CMEs are more oriented in incremental 
innovation. Fluid decision making systems, job markets, and financing systems 
are a few key reasons for LMEs possessing the capability of radical innovation. 
For example, in LMEs rapid access to new financing makes it possible to invest 
faster in new key areas. In order to investments to be effective, fluid labor 
markets are needed to provide a quick route to access needed capabilities 
through job markets. On the other hand, in CMEs system supports long term 
investments and thus makes it possible to acquire considerable amount of 
industry-specific skills to provide capabilities for incremental innovation.  
In practice these complementarities are also observed in some examples and 
empirical data that Hall and Soskice present. A key example that Hall and 
Soskice (2001, fig. 1.5 and 1.6) provide is about the patenting activity between 
Germany and the United States. It is seen that these characteristics make 
Germany to specialize in technological developments that are exactly opposite 
to those in the United States. In Germany, the innovation has been in the fields 
that are characterized by incremental innovation like mechanical engineering 
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and transport. In the United States radical innovation specific industries, such as 
medicines, semiconductors, and telecommunication, have been stronger. 
Therefore, strong US players have characterized these industries. The second 
high level proposition for the study can be formulated from innovation 
capabilities to tie the empirical context more closely to the theory of VoC.  
Proposition 2: Industries needing more incremental innovation, such as generic 
medicines industry, should be more successful in the coordinated economies. 
At the company strategy level, VoC theory suggests that there are many 
pathways to high performance. These pathways are based on different settings 
in institutional environment. There is some contradiction in this and the 
traditional international business studies, where usually the high performance 
is a result of strategy fitting to the institutional context (Jackson & Deeg, 2008). 
An example given here by Jackson and Deeg (2008) is from Lehrer (2000), who 
found out that in the airline industry two divergent paths from Lufthansa and 
British Airways led to equally successful performance and led to outperforming 
the mixed strategy of Air France.  
Various contributors have explored and studied the theory with various points 
of view and examples. To provide more concrete reasoning for above presented 
division into LME and CME and to their complementary attributes one example 
is presented here from the group of cases in the original book. Sigurt Vitols 
writes about the varieties between the UK and German chemical/ 
pharmaceutical industries (Hall & Soskice, 2001, pp. 355-358). This example is 
also interesting because of its close relation to the generic medicines industry. 
Vitols argues that based on the theory of VoC the decline of German industry 
and the growth of British industry in the 1990s can be explained. British 
companies were characterized the ability to enter the new growth fields more 
rapidly because of their ability to innovate radically. In addition to that, more 
rapid rationalization in the production of simpler products was an important 
comparative advantage. The pace of change in German companies had been 
slower but change has also increased the importance of chemicals in compared 
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with pharmaceuticals. The ability to change rapidly because of the 
characteristics of the national institutions made German companies exit the 
pharmaceutical markets. Some exited totally and some continued as chemical 
producers. Also some transferred their key operations to US to compete in 
rapidly changing markets with similar capabilities as LME based companies. In 
general it can be said that there can be multiple paths to high performance, both 
for nations and companies.  
2.2 Current Issues and Critique of the Varieties of Capitalism 
Even though currently VoC theory has been legitimized and it has developed 
quite a dense body of knowledge, its future looks somewhat uncertain. The 
whole theory probably is not disappearing; it is still a valid theory and it is 
indicated to have many strengths that should not be abandoned (e.g. Blyth, 
2003; Jackson & Deeg, 2008). However, the future should hold quite many 
changes to the key parts of the theory that emerge from the growing number of 
criticism that is experienced by the original theory. This chapter addresses the 
criticism of VoC theory as well as the additions and the proposed additions to 
the original theory.  
Criticism and additions to the original theory have been divided into three 
slightly differing areas. Firstly, the labeling in VoC, namely the bipolar division 
into LME and CME, has been experiencing quite many additions (e.g. Amable, 
2003; Schmidt, 2008). Secondly, coordination and institutional coherence as a 
measurement of success experience criticism (see generally Kenworthy, 2006). 
Thirdly, the analysis itself is experiencing two tiered criticism from the type of 
analysis, whether it should look at macro-, meso-, or micro-level, to the level of 
dynamism in the analysis (e.g. Deeg & Jackson, 2007; Jackson & Deeg, 2008). 
The main proposals for theoretical contributions emerge from the last point.  
2.2.1 Labeling in the Varieties of Capitalism 
Firstly, problems are seen in the bipolar division into LME and CME. One of the 
problems is that this division does not include even all the OECD countries, not 
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to mention Eastern-European economies or Asian economies. Second problem 
is that the studies conducted in the spirit of the original theory are mostly 
comparative studies between the main ideal types (see generally many of the 
case examples by various contributors in Hall & Soskice, 2001). In general these 
arguments yield the criticism that the theory is not capable of producing robust 
results (Jackson & Deeg, 2006; cf. Kenworthy, 2006).  
To make the theory more capable of making more robust conclusions there is 
various additions to the original binary division between LME and CME. Instead 
of having these two capitalisms, at least three varieties of capitalism (Rhodes & 
Van Apeldoorn, 1997; Schmidt, 2007, 2008), four (Boyer, 2005; Ebbinghaus, 
1999), or even five (Amable, 2003) is argued to be. In addition to these clearly 
labeled theories, there can be even more varieties as indicated by Schmidt 
(2008), for example, due to national varieties (Boyer, Crouch, & Streek, 1997) or 
regional and local varieties (Crouch, 2005).  
Some of the main additional divisions that have been adapted for studies are 
firstly three tiered division where LME and CME are added with “state-
influenced” market economies (Schmidt, 2007). This division works with 
European countries and has the states interference to the markets as the 
differentiator between capitalisms. This way this model tries to make a cap 
between it and previous three tiered models where LME and CME are added 
with “mixed market economies” (Hall & Gingerich, 2004) mainly to include the 
countries that are outliers in the original model. Similarly Europe is also 
categorized earlier with different labels to Anglo-Saxon, Germanic, and Latin 
capitalism (Rhodes & Van Apeldoorn, 1997). Also one type of division into three 
labels is Esping-Andersen’s model where LME is as presented by Hall and 
Soskice, but the CME is divided into the Scandinavian type social democratic 
model and to the continental European model (Hopkin & Blyth, 2004).  
In four tiered models, Europe is divided into Nordic, Center, Southern, and 
Anglo-Saxon models (Ebbinghaus, 1999) or to market-led, meso-corporatist, 
social democratic and state-led (Boyer, 2005). Boyer’s work also gives room to 
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the fifth emerging form that should cover the transformation economies of the 
former Soviet-type economies in Eastern Europe and in China. Still in the 
models with four labels the same problem remains as in the three-label and 
original binary model: market economies outside Europe have only little 
importance. 
Currently one of the most complex and robust theories is one Amable (2003) 
has presented. This theory is among a few in the group of labeling theories that 
can incorporate emerging market economies into the groups (see Jackson & 
Deeg, 2006). In a five-model theory, there is a market-based model, a social-
democratic model, a continental European model, a Mediterranean model, and 
an Asian model (Amable, 2003).  
So generally Eastern-European or emerging Asian countries can be only 
incorporated to the theory with five or more distinct capitalism models. For the 
purposes of the study possibility to incorporate Eastern-European countries to 
the analysis is essential as the European generic medicines markets are highly 
affected by them. This will be discussed later in this thesis. Therefore, it is 
somewhat encouraging that some efforts to study former communist countries 
in the context of VoC have been made (e.g. Lane, 2005; Lane & Myant, 2007).  
To extend the theory to Eastern-European transition countries, Lane (2005) 
argues two additional models that can fit former communist countries, which 
have been able to adapt some form of capitalist society. He argues the models 
based on Amable’s work (2003). First model for the former communist 
countries is close to Amable’s continental European model, but has more state 
control in place. This model has the most number of former communist 
countries and includes all the countries that have already been accepted to the 
European Union. Second model Lane proposes is a hybrid state/market 
uncoordinated capitalism. The biggest country representing this model is 
Russia. Lane mentions that his model needs to be substantiated and there he 
sees detailed country studies as the most viable way forward.  
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However, binary, or any other labeling method for that matter, have other 
problems than finding trouble fitting all the countries to the model. Firstly, it has 
been argued that there are even greater varieties in capitalist models within 
nations (Schmidt, 2008). Secondly, it has been argued that since the creation of 
the theory world has changed in a way that the division by Hall and Soskice 
(2001) is no longer valid. Mainly due to the changes in economic environment 
that are caused by globalization, or Europeanization in Europe (Schmidt, 2008), 
the models indicated in VoC are becoming obsolete. It has been argued that in 
Europe the economies are converging to a common liberal model. However, 
there is a varying opinion saying that even though changes are there, there is no 
convergence to be seen (Hall, 2007). 
2.2.2 Measuring Performance in the Varieties of Capitalism 
The second area of the critique associated with VoC is the performance 
measurement. Measuring performance and efficiency in VoC have been done 
both with the level of coordination and institutional coherence. Both of these 
are somewhat relative to the critique of binary division as these measures are 
used as a basis for those divisions.  
Hall and Soskice have chosen innovation as a representative of a success in the 
analysis of coordination. They chose innovation because of its importance to 
economic success and because they have failed to explore other areas (Hall & 
Soskice, 2001, p. 44). This is problematic as other areas of performance 
measurement might provide totally contradictory results for the sources of 
comparative advantage. Also the use of patent data to illustrate innovation, as 
Hall and Soskice propose, is questioned. Allen, Funk and Tüselmann (2006) 
argue that patents might not in reality translate well into comparative 
advantage. They, however, also note that this has not been the only 
measurement of success and efficiency in VoC literature since Hall and Soskice. 
As a whole, there is more support to coordination than there is critique.  
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Institutional coherence is another building block of different capitalist models 
that emerge from the original theory. Originally this part of the theory was 
argued with qualitative analysis and comparative case studies (e.g. Hall & 
Soskice, 2001). The problem with the comparative case studies in VoC has been 
that comparisons have been very limited and strictly defined. The comparisons 
have been made between few countries and in a particular time in history. Also 
many examples do not account for any other countries except ideal types. What 
is more, when comparing the characteristics of LME and CME with the firm 
specific characteristics in specific industries, there can only be a limited 
explanation of the success of the industry. The problem is that without being 
able to analyze countries outside the ideal types with all the affecting factors, 
theory is not capable of making sweeping statements. 
There have been some studies made to test the institutional coherence in 
practice and with more analytical frameworks. Especially Hall and Gingerich 
(2004) in their study conclude that their empirical analysis supports the 
original hypothesis of coherent economies outperforming less coherent. 
However, Kenworthy (2006) quite much critiques the study by Hall and 
Gingerich (2004) as well as the original theory. He uses two measures of 
institutional coherence, one developed by Hall and Gingerich and another he has 
developed. By analyzing these, he finds almost no support for the notion that 
superior macroeconomic performance is a result of institutional coherence. In 
addition to that, Kenworthy critiques the research setting of Hall and Gingerich. 
More specifically Kenworthy argues that the forming of the institutional 
coherence measurement is incomplete. The factor analysis of Hall and Gingerich 
that is used to construct the measurement only incorporates three of five Hall 
and Soskice (2001) spheres and, what is more, the corporate governance sphere 
is represented in half of six indicators.  
It seems that coherence measurement for the industry’s success has more 
problems than a coordination measurement. Furthermore, coordination seems 
to address more the specific industries as the coherence addresses national 
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economies. For the study, a general proposition from these observations can be 
formulated. 
Proposition 3: The value of the coherence measurement should be lower than the 
coordination measurement when analyzing the success of an industry.  
2.2.3 Analyzing in the Varieties of Capitalism 
Last part of the critique is actually more of an effort to clarify, unify, and to point 
a direction forward for the analysis within VoC than criticizing the previous 
analysis. It is first and foremost argued that more dynamism is required in the 
VoC analysis (Fiss, 2007), to incorporate all the current changes in the world 
economy. The critique addresses that weakness in many of VoC studies is the 
static analysis and the bias of predicting institutional stability rather than 
change (Deeg & Jackson, 2007; Jackson & Deeg, 2006). Especially Deeg and 
Jackson (2007) propose that in order to have more dynamism in the VoC theory 
the division of the analysis between micro-, meso-, and macro-levels needs to be 
clarified. A micro-level requires a stronger understanding how actors reshape 
the institutional environment. A meso-level requires the understanding about 
linkages between various institutions, which then could be used to theorize how 
change in one affects the other. A macro-level then moves to the level of national 
and international politics and, for instance, analyzes rule making processes. The 
main argument, about why this clarification is needed, is that current forces of 
globalization are much stronger in changing national institutions than the 
theory predicts. One clear indicator to this point that fits especially well to the 
pharmaceutical industry is the growing importance of multinational 
corporations as well as institutions that go beyond the national borders.  
Furthermore, before Deeg’s and Jackson’s two papers Kenworthy (2006) 
indicated similar ideas. He indicated that analyzing at the macro-level with 
aggregated outcomes is extremely difficult because of the complex causal 
linkages. Empirical findings from macro-level analysis need to be tested 
thoroughly before accepting those results. This can prove to be difficult and 
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therefore usually macro-level analysis remains only a partial or preliminary 
step in the investigation of causal linkages. This is another argument that directs 
future research to more detailed studies in the meso- or the micro-level. 
Some of the criticism to the original theory presented above have been tried to 
answer with some recent work. For example, proposed theory’s disregard of the 
state influence (Jackson & Deeg, 2008) has been answered in part in Vivien A. 
Schmidt’s work (Schmidt, 2008, 2007). In addition, the presented critique on 
the institutional stability has been argued against at least at macro-level: Hall 
and Thelen (2009) have developed the theory to cover this institutional change 
in more extended way than the original theory. However, the problems of 
setting the theory with the empirical evidence (Jackson & Deeg, 2008) are still a 
major concern especially at the meso-levels of the analysis (Deeg & Jackson, 
2007). Deeg and Jackson also indicated that the current institutional 
environment is too complex for the types of theories that VoC represents. It 
seems that the traditional methods of analysis might not be sufficient for VoC 
context.  
2.3 Future of the Varieties of Capitalism 
The critique provides multiple viable ways for VoC theory to go forward. The 
problem is that on the basis of all the criticism presented above, it might not 
look clear that the VoC theory is viable today, for example, because of the 
increasingly complex environments. However, arguably only the strict labeling 
of capitalisms might not be relevant in today’s world, but it still seems viable to 
construct the future of the theory based on complementarities in economies. 
Theory has created a standard that provides wide variety of hypotheses for 
understanding institutional environment as a factor effecting companies’ 
success. However, the future contributions to this theory must be a subject to 
more sophisticated empirical tests. (Deeg & Jackson, 2007; Jackson & Deeg, 
2006.)  
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As Varieties of Capitalism includes a very broad number of issues at the macro 
level, not all of these can be incorporated to industry specific analyses. From the 
previous critique things that are particularly relevant to the thesis include the 
categorization as a mean to simplify the complex environment, the 
measurement of high performance, and the combined influence of macro-, 
meso-, and micro-level to an industry. First the categorization or labeling, 
whatever it might be, could be useful in analyzing issues leading to performance 
differences between regions. Categorization has been effective in labeling 
established economies. Problems with labeling emerging economies, in this case 
meaning mainly the Eastern European nations, need to be assessed. For 
performance analysis it is important also to examine other things that might 
have an effect on performance, not just coordination and coherence. It is also 
important to understand that there can be multiple paths to high performance. 
To analyze complex environment as well as multiple paths to an outcome, 
analysis framework should also be assessed. Main issues of VoC as well as main 
takes for the thesis are summarized in Table 2. 
Table 2: Summary of the Key Findings in Varieties of Capitalism 
Critique area Current status General issues  Key ideas for this thesis 
Labeling 1-5 or even 
more groups of 
capitalist 
variation. 
Future of the labeling, 
possible convergence to 
a capitalist model, 
including emerging 
economies to the 
theory more strongly.  
Categorization can be 
helpful in assessing 
performance, but there can 
be limitations when 
including Eastern Europe to 
analysis. 
Measuring 
performance 
Economic 
coherence and 
coordination 
key areas in 
performance 
measurement. 
Validity of 
measurements used 
previously, providing 
new ways to measure 
coherence and 
coordination. 
There can be multiple paths 
to high performance, both 
for nations and companies, 
and multiple things affect 
to performance and 
efficiency. 
Analysis Mostly 
qualitative 
comparisons 
between small 
numbers of 
cases. Some 
attempts to 
analyze more 
analytically. 
Methods of analysis in 
different levels from 
macro to micro, 
analyzing increasingly 
complex environments, 
the analysis of change 
or stability in the 
economic systems. 
The focus on the more 
tightly framed settings 
when keeping in mind also 
the institutional 
environment should 
provide input on the firm-
level strategies. New 
analysis methods are 
needed. 
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Analysis methodology is a key thing when studying the generic medicines 
industry in the VoC context as can be seen in Table 2. Amable (2003) already 
showed that VoC theory is not limited to stay with the traditional variable-based 
approaches. He successfully introduced to the VoC discussion clustering 
approach. Fiss (2007) continued in another new direction and argued that set-
theoretical methods are one possible way for assessing ideas and issues in this 
context comprehensively. Set-theoretical methods can be more complex than 
traditional analyses. Also the proposed advances in VoC, like moving the focus of 
the analysis towards micro-level, are seen to increase complexity in the analysis. 
As set-theoretical methods are able to address more complex settings, set-
theoretical analyses are also able to produce more complex results in the 
context of VoC (Crouch, 2005; Jackson & Deeg, 2008). Therefore, set theoretical 
approaches also provide important research paths for advancing theories and 
testing proposed hypotheses that relate to institutions and firm performance, 
and causal complexity between those (e.g. Fiss, 2007; Jackson & Deeg, 2008). 
In this chapter three propositions were also presented. These give a high-level 
view about the issues that might have some affect to industries in general. The 
underlying idea is that these issues affect the industry’s performance in 
conjunction with industry and company specific factors. This is one reason that 
suggests that the industry dynamics need to be studied. These propositions also 
partly direct the research of industry dynamics. For example, like coordination 
in the economic environment might have something to do with the success of an 
industry also the industry specific coordination might influence the 
performance. Therefore, the next chapter will deepen this analysis to the 
generic medicines industry context and present more propositions relating to 
industry context. All the presented propositions will provide a direction for the 
analysis. The propositions that have been presented so far from VoC are listed in 
Table 3. 
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Table 3: Propositions Made from Varieties of Capitalism 
General propositions from the VoC theory 
Proposition 1 Coherence and coordination in the economy affect the performance 
of an industry. 
Proposition 2 Industries needing more incremental innovation, such as generic 
medicines industry, should be more successful in the coordinated 
economies. 
Proposition 3 The value of the coherence measurement should be lower than the 
coordination measurement when analyzing the success of an 
industry. 
These three propositions together formulate the first hypothesis addressing the 
key issues in the generic medicines industry. 
Hypothesis 1: The performance of the industry is enhanced in coordinated market 
economies. 
For the thesis, this means that the understanding about the institutions as a part 
of companies’ success and therefore also for the industry’s success is essential. 
Different types of institutions within European countries have different 
capabilities to provide for the companies operating within their domain. This 
should make industry performance vary from country to country. Especially in 
the generic medicines industry the public policies can be a major factor in 
boosting the industry within a country or restraining its progress in another.  
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3 European Generic Medicines Industry 
The study uses generic medicines industry and its business environment as a 
source for empirical data. In order to find the possible success factors, a 
comprehensive understanding about the industry is required as proposed in the 
literature review. Deep understanding is also required to conduct a valid 
analysis using the fuzzy set methodology, which will be discussed more in 
Chapter 4. 
To illustrate the most relevant aspects of the industry, this chapter is structured 
under four main topics. First the operational environment will be discussed. 
This includes the structure of the industry, stakeholders, and brief analysis of 
the company population. Second part presents the regulatory and institutional 
environment. This part has a partly evolutionary perspective and will introduce 
the patent and promotional regulation and the institutional environment. Third 
part discusses economic environment. Here will be presented the main market 
characteristics, market shares, and pharmaceutical expenditure. Fourth part is 
about the social environment. This part discusses the demographic factors. 
Technological environment is not seen that important for generic medicines 
that it should be discussed under its own chapter. The relevant aspects of the 
technological environment are included in the operational environment.  
3.1 Operational Environment 
3.1.1 Industry Structure  
Defining generic medicines industry is not an easy task and it can be done 
multiple ways, as with almost any other industry today. One thing common to 
all definitions is that generic medicines are medicines that have lost their patent 
protection. Essentially the focus will be on the producers of generic prescription 
medicines, but the generic medicines industry can be understood also much 
more broadly. Within the whole generic medicines industry, there are multiple 
types of operators. To understand the actors and their role for the industry 
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more and to distinct the prescription generic medicines from the others, 
industry needs to be explained first in a broader picture.  
Maybe in the broadest sense generic medicines industry consists of all the 
operations concerned with medicines which are produced and distributed 
without patent protection. This consists of production of general prescription 
medicines and over-the-counter sold medicines (OTC) that do not require a 
prescription and are most often used for self-care. Also included in this broad 
definition is the distribution network of medicines, which means wholesale 
companies and pharmaceutical retail outlets that in most cases are pharmacies. 
This is where generic medicines industry overlaps with the traditional 
innovative medicines industry as they both use the same distribution channels, 
at least to some level. Retail trade could also happen in an OTC outlet or through 
self-dispensing doctors in areas where this is allowed by legislation.  
One part of distribution is also parallel importing (PI). This is especially 
characteristic of the European markets, where companies import readymade 
medicines from a cheaper country to more expensive country and intend to 
capitalize on the price difference. The free movement of goods within the EU 
and the price differences between old and new member states makes this kind 
of business possible. Parallel importing thus has an economic impact at the 
European level for generally lowering prices paid by the patients, which is 
similar to the effect of generic medicines. Parallel importing can also occur with 
patent protected medicines. (Enemark, Pedersen, & Sørensen, 2006.) In addition 
to this, there are companies that sell generics without producing them 
themselves. These companies can be anything from pharmacies to individual 
brand name holders. They usually use contract manufacturing (contract MFR) to 
produce their products.  
On the supply side of the value chain, the production of medicines requires 
active pharmaceutical ingredients (API). Many companies can produce these by 
themselves for their medicines, but there are also companies specialized in 
producing only these. API companies in some cases are specialized in producing 
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other chemicals and thus operate with different business logic than medicines 
producers. API producers are business to business companies operating in the 
process industry setting, and require different technical capabilities than 
medicine producers. However, in the broad picture, these are an important part 
of the industry.  
In parallel to generic medicines retail industry that produces products for 
patients operate part of the industry that works with hospitals. Hospitals use a 
lot of infusions and similar bulk products and all of these can be considered 
generic medicines in the broad definition, but obviously these are closer to 
consumables than prescription medicines. Consumables and other medicines 
that are used in hospitals are mainly bought through a tender process directly 
from pharmaceutical companies. In addition to that, hospitals supply a small 
amount of their required medicines from wholesalers. Even though not being a 
very visible business, it is still relatively large in size. In 2007 hospital 
medicines’ business was approximately third of the retail business. (European 
Commission, 2009, p. 22.) 
Furthermore, generic medicines industry has research and development (R&D) 
focused companies that help, among others, on the development of molecules, 
molecule combinations, or production processes. On the support side there are 
also companies categorized under service companies that serve all of the above. 
These companies are, for example, marketing, consulting, market research, and 
legal advisory companies. Especially legal advisory is important due the fact 
that regulatory environment is so diverse. Legal advisory ranges from patent 
advisory to market entry advisory. 
Furthermore, biosimilars, which are the generic versions of biopharmaceutical 
products, are a part of the industry. In general they have similar type of supply 
and distribution networks than tradition medicines. However, biosimilars are 
still only an emerging part of the industry as the first biosimilar was accepted in 
the EU in April 2006 (Blackstone & Fuhr, 2008). In biosimilars the EU is overall 
ahead of the rest of the world, for example because of the acceptance, but 
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because of the emerging nature of the industry biosimilars are excluded from 
the study. 
An illustration of generic medicines industry’s value chain with the actors 
presented above is presented in Figure 2 below. Obviously all of these actors 
discussed above have an impact on the development of the industry and thus 
they all need to be taken into account at some level. However, the main focus of 
the thesis is on the actors who operate clearly in the production and selling of 
the generic prescription medicines. The analysis will focus on the dynamics that 
affect this part of the industry. The focus group is indicated in Figure 2 with a 
red outline. The same definition of generic prescription medicines was used as 
when forming a database of European generic medicines companies for GloStra 
database in the 2009 and 2010. This database will be used in the analysis and it 
is discussed in Chapter 5 in more detail. 
 
Figure 2: Simplification of the Generic Medicines Industry’s Value Chain with Key Support Areas 
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3.1.2 Key Stakeholders 
In addition to value chain, there are many stakeholders that have an influence 
on the industry in one way or another. Stakeholders can be divided into three 
categories. These three categories are government level stakeholders, industry 
level stakeholders, and other stakeholders. This division is presented in Figure 3 
below. The division and the presented stakeholders are based on a general 
understanding about the industry and are presented to give a more general 
view of the generic medicines industry’s position in the markets.  
 
Figure 3: Stakeholders Influencing the Development of the Generic Medicines Industry  
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so that both industries have a possibility to thrive by keeping in mind their 
ultimate goal of keeping the public health expenses in minimum. 
The main influencers to the industry in a European context are national 
governments and agencies as well as the EU authorities. They have direct 
influence on the industry dynamics through regulatory processes. As one of the 
main payers, they have also incentive to use this influence. National 
governments work mostly on generic medicines promotion aspects and the EU 
authorities work more on unifying the inner markets and patent legislation. 
These are discussed more in Chapter 3.2 Regulatory and Institutional 
Environment.  
Other stakeholders have mostly indirect ways of influencing the industry 
dynamics. Lobbying can be used to influence the legislation process. Citizens’ 
influence is many times limited to choosing to use generic medicines instead of 
original medicines. This can generally be described as patient’s acceptance 
towards generic medicines. Media can have an influence on patients’ 
acceptance. Evidence from Portugal at least indicates that pro-generic 
campaigns have raised demand (Simoens & De Coster, 2006). Media’s influence 
can also work towards legislative bodies by communicating the patient’s 
acceptance to decision makers more effectively. From the industry structure 
and the stakeholder analysis, the first proposition of the industry dynamics, or 
fourth proposition in total, can be made. All propositions presented in this 
chapter will discuss to the generic medicines industry specific issues. These 
propositions will in combination with the previous ones direct the analysis 
towards the most relevant issues. 
Proposition 4: The main influencers to the overall success of the generic medicines 
industry are the major payers of the health care costs at the government level.  
3.1.3 Evolution of the Company Population 
This chapter consists of two parts. First and main part is the analysis of the 
company population in the generic medicines industry. This part will show the 
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general trend in industry’s structural change in Europe. Second part is a brief 
introduction to the major players in the generic medicines industry and will give 
a more detailed look of the current status. 
Evolution of Density 
In the discussion of organizational ecology based industry evolution, population 
density is a crucial framework (see generally Carroll & Hannan, 2004; Hannan & 
Carroll, 1992). Density dependence (Hannan, 1986) is one of the most 
important models relating to organizational evolution. It is used to explain the 
organizational entries to the organizational population. According to density-
dependence model the drivers for change are legitimation and competition 
(Carroll & Hannan, 2004, chap. 10).  
The basic theory by Carroll and Hannan (Carroll & Hannan, 2004, chap. 10) 
identifies legitimation and competition as opposing forces. Legitimation 
increases when the density increases. However, the legitimation cannot exceed 
a finite ceiling and competition works as opposing force when the density has 
increased so that the environment can no more support all the actors. Resources 
eventually become extremely scarce as more and more companies enter the 
industry.  
According to the theory, the entry rate in to the population is then proportional 
to the level of legitimation and inversely proportional to the intensity of the 
competition. This means that the model implies S-shaped density curves, where 
density growth is first low then increases in increasing speed when legitimation 
effect is strong and in the end slows down again when competition effect 
becomes stronger and stronger and at the same time legitimation rate 
approaches the finite ceiling rate. This basic theory does not take directly in to 
account the exit rates, which occur, for example, due the consolidation of the 
industry.  
Generic medicines industry’s density with entries and exits is presented in 
Figure 4 below. Data for the figure is obtained from the GloStra database of 
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European based generic medicines companies. The database is discussed more 
in Chapter 5 Data and Analysis. Figure 4 presents the evolution of density from 
1950 to 2008. The figure is cut at this point because of the interest in the 
current events and because the modern generic medicines industry did not exist 
at the earlier half of the 20th Century. History will be discussed more in Chapter 
3.2 Regulatory and Institutional Environment, but it will be noted here that 
most of the companies founded even before the 1980s have their roots in other 
businesses and have since then transformed to the generic medicines.  
 
Figure 4: Density and Entries and Exits of the Generic Medicines Industry in Europe (1950-2008) 
By looking at Figure 4 some conclusions about the generic medicines industry’s 
state can be made. First of all, the S-shaped curve is seen here and the escalation 
in entries beginning from the late 1980s is seen. This is in line with the 
historical information about the rise of the modern generic medicines industry 
since the introduction of Hatch-Waxman Act in the United States in 1984 (see 
more in Chapter 3.2.1 Patent Regulation). It seems that since then the carrying 
capacity of the environment has been reached and entries have gone down. 
With the exits taken into account the density has gone down even more. Exits 
are mainly due the merger and acquisition (M&A) activity in the industry. In 
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global markets, the similar trend is also seen and M&A activity has risen 
substantially (Karwal, 2009). This was also seen when exit times were encoded 
in the database. Karwal (2009) further argues that similar trend in high M&A 
activity will continue. He says that since the industry is essentially highly 
fragmented the changing market conditions will in support this trend and 
further change the shape of the industry in the future. Therefore, it seems clear 
that industry’s consolidation has started and the carrying capacity of the 
industry has been reached. 
The Largest Companies 
Information from the biggest generic medicines companies provides proof and 
verifies that the consolidation is one of the major industry trends. Major 
acquirers in the industry are the biggest companies: Teva from Israel and 
Sandoz a generic subsidiary of Swiss pharmaceutical company Novartis. 
Moreover, an industry trend seems to that smaller companies are being 
acquired by bigger ones rather than equally sized companies merging. This is 
seen also in the diminishing company density. (Karwal, 2009.)  
In addition to being consolidated within the generic medicines industry, 
originator companies have started to acquire generic companies. For example, 
Zentiva was acquired by originator company Sanofi-Aventis in 2009. One reason 
for the consolidation and the emergence of originator companies is the faster 
growth of generic products in comparison to originator products. Growth 
projections and reasons will be discussed more in Chapter 3.3 Economic 
Environment. (European Commission, 2009, p. 38; Karwal, 2009.)  
The largest generic companies are listed in Table 4. Due to the issues discussed 
here, this data is already somewhat outdated. The data of the table is from 2007 
and because of the strong consolidation that is ongoing in the industry many 
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companies have changed their ownership since then1 (European Commission, 
2009, p. 37).  
Table 4: The Largest Generic Companies in the EU 2007 by Turnover in Prescription Medicines (Reproduced 
from European Commission, 2009, p. 37) 
Company Rank Turnover EU  
(€ thousand) 
Turnover USA  
(€ thousand) 
Turnover global  
(€ thousand) 
Teva 1 3,388,421 1,449,732 5,763,037 
Sandoz† 2 2,041,182‡ 1,318,915‡ 5,406,935* 
Ratiopharm 3 1,021,388 n/a 1,383,599 
Stada 4 900,000-1,000,000 6,519 1,570,490* 
Mylan 5 800,000-900,0001 1,259,525 1,435,8112 
Actavis 6 496,918 339,905 1,544,154* 
Zentiva 7 341,379 0 511,646 
Gedeon Richter 8 314,676 14,640 607,067 
Pliva 9 282,191 104,670 564,772 
Ranbaxy 10 237,432 286,579* 1,181,651* 
Total  9,940,683 4,780,485 19,969,163 
Notes: 
* = global turnover for prescription medicines was not provided by the companies so the figures used refer to medicines in 
general. 
† = these figures were originally calculated in US$. The conventional foreign exchange rate used to translate Sandoz initial US$ 
denominated figures into € was US$ 1 = € 0.72966. 
‡ = for prescription medicine only excluding the contribution from the Anti-Infective business and/or OTC activities in some 
markets. 
1 = EU turnover of Merck Generics for prescription is between € 800 million and € 900 million for 2007 which includes, from 
the acquisition of Merck Generics Group by Mylan, the EU turnover for the fourth quarter publicly disclosed and amounting to 
€ 272.3 million (US$ 373.1 million). 
2 =Turnover (total sales), in thousand, globally but excluding Merck Generics. 
From the company population analysis, the next proposition about the industry 
dynamics can be made. This proposition combines two ideas. First, the survival 
of the company is one of the first requirements of the success and in an industry 
with high M&A activity companies need to be especially concerned about their 
survival. Second, as argued, among others in the VoC theory, there might be 
comparative advantages between nations that affect to industries.  
Proposition 5: Nation’s industry specific comparative advantages have an effect on 
the survival of the company population in that nation. Likewise, the survival of the 
company population manifests nation’s industry specific comparative advantages. 
                                                        
1 Teva has merged with Barr Pharmaceuticals and previously Barr acquired Pliva in 2006. 
Zentiva was acquired by Sanofi-Aventis and Ranbaxy by Japanese Daiichi Sankyo.  
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3.2 Regulatory and Institutional Environment 
This chapter discusses the regulatory and institutional environment of the 
generic medicines industry. Regulatory environment will be discussed in two 
categories:  
i. changes in patent and intellectual property (IP) rights legislation and  
ii. changes in generic medicines promotion.  
This division and the subcategories of these are presented in Figure 5.  
 
Figure 5: Two Major Regulatory Fields Affecting the Markets of Generic Medicines: IP and Promotion 
The underlying idea for the division is the mechanism how these affect the 
industry. The mechanisms came out strongly when researching this topic. This 
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medicines success and causes for success are related to promotion (Redwood, 
2004).  
After the discussion about the regulatory environment, the institutional 
environment will be described. In this part, the more general level changes 
affecting the generic medicines industry will be discussed. This will include, 
among others, the EU enlargement and the overall unification of European 
markets.  
3.2.1 Patent Regulation 
Starting Point of the Modern Generics Medicines Industry 
Patent and IP related legislation are in the center when thinking about the 
beginning of the generic medicines industry. The idea that patents are in the 
center is easy to point. The fact that the definition of generic medicines requires 
that they have lost their patent protection is a clear indication for this. Without 
lost patent protection medicines cannot be generic but they are, for instance, 
copies. 
However, the exact starting point of the generic medicines industry is not easy 
to define. This is because industry, at least in theory, had its first possible 
starting point when the first ever medical patent was expired. To determine 
exact time is nearly impossible as patent regulations have been so varying from 
country to country. However, it is not even necessary to determine the entry 
time of the first generic medicine as the earlier business was clearly different 
from modern generic medicines industry. Nevertheless, in general generic 
medicines have been around all of the 20th Century.  
To put things into perspective, Figure 6 presents change in the share of generic 
medicines in the markets in the 20th century. The figure shows the interesting 
historical development of the share of generic medicines in comparison to 
original medicines. Therefore, the figure illustrates the decline of the generics 
due the tightening IP regulation, and then the interesting rise in the share of 
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generics since the 1980s. This is the beginning of the modern generics industry, 
which started from the United States. The figure is presented as an interesting 
illustration of the development and should be read critically, for example, 
because the geography it illustrates is not explicitly mentioned. However, the 
information it provides correlates with the information from the literature.  
 
Figure 6: Proportion of Generic and Branded (Original and Branded Generics) Medicines Prescribed 1900-
1997. Sources: Office of Health Economics, Department of Health, UK (1999). (Reproduced from Taylor & 
Harding, 2001, p. 17) 
In the 1980s, the patent legislation concerning medicines was in turmoil in the 
United States. The United States had been showing the way in patent legislation 
all the way from 1790 from the introduction of the first patent law, so in that 
regard it is not surprising that this change also began from there (Mándi, 2003). 
According to many experts, one of the main triggers for the modern emergence 
of generic medicines, a trigger for the development that is still on-going, has 
been the Drug Price Competition and Patent Term Restoration Act of 1984, 
informally known as the "Hatch-Waxman Act" [Public Law 98-417] (Schacht & 
Thomas, 2002). Hatch-Waxman Act reduced both the entry requirements and 
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the time to entry for generic medicines to the market and thus established the 
modern system for generic medicines. This act meant that generic medicines 
would be allowed to the market more rapidly under the Abbreviated New Drug 
Application (ANDA) process rather than New Drug Application (NDA) process. 
Also Hatch-Waxman Act made it possible for the market approval process for 
generic equivalents to occur before the expiration of the patent on the original 
brand, which is better known as the Roche-Bolar early working provision or in 
short Bolar provision. This provision was named after Roche Products v. Bolar 
Pharmaceutical court case Co., 733 F.2d 858 (Fed. Cir. 04/23/1984) that was 
decided shortly before enacting the Hatch-Waxman Act (Mossialos, Mrazek, & 
Walley, 2004, p. 252). Especially Hatch-Waxman Act gave a 180-day period of 
market exclusivity for the first generic medicines manufacturer to challenge the 
validity of the existing patent (Schacht & Thomas, 2002). 
In a simplified view, as in Figure 6, there are two main groups of actors in this 
business: generic medicines companies and innovative medicines companies. 
Basically as these groups can be considered total opposites in regard to patent 
legislation, one decision helps other and at the same time is unbeneficial to the 
other. The general understanding about the beneficiary of the patent legislation 
follows the idea presented in Figure 6 until the 1990s. Since the legislative 
changes began favoring generics in the 1980s generic medicines industry 
continued to benefit from patent legislation changes throughout the latter half 
of the 1980s. It is indicated that at the beginning of the 1990s the legislation 
began slightly favoring patent holders again (Redwood, 2004).  
Patent Regulation Development in Europe 
Following the example set by the United States, similar legislation was also set 
in Europe, but much later. The problem in Europe was that patenting practices 
were different between the countries. When analyzing the patent regulation in 
Europe, it is important to understand the difference between basic patent being 
a product patent or a process patent. Basic patent, which is the first patent 
issued after the preparation and testing of the new active ingredient, is the basis 
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for the protection of the medicine, which is supplemented with various other 
patents. Basically, if the basic patent has been expired, the competition is open 
for generic products. Currently in all of the developed countries basic patent is a 
product patent, but this has not been the case always and process patents have 
provided possibilities for generic competition. (Mándi, 2003.) 
American product protection dates back to 1790, but in some European 
countries this is a rather recent thing. Austria adopted product patent in 1987, 
Spain in 1992, and Finland and Portugal in 1995. Also Greece adopted product 
patents in the 1990s. Former Soviet Union states adopted product patents 
between 1990 and 1995. Even though Eastern European countries had limited 
patenting practices and Western European countries in general used to have at 
least process patents in place before adapting product patents, the development 
in Western Europe from process patents to product patents is more interesting. 
This is because the markets have been more unified in Western Europe and thus 
patenting differences have had more effect on the markets. (Mándi, 2003; 
Simoens & De Coster, 2006.) 
Furthermore, in some countries those are mostly in southern Europe, patent 
protection as a whole is a relatively new thing. Because of the lack of the 
support for the international patent protection, copied medicines have been 
allowed in these countries and even today generic medicines markets are 
affected by this. For example, in Italy the patent protection was granted as late 
as 1978 and generic medicines as a term as late as 1996 (Ghislandi, Krulichova, 
& Garattini, 2005).  
Differences in IP regulation, especially the process patents, between countries 
have been used to get the generic medicines into European markets. These 
differences provided possibility to enter the markets earlier than it would have 
been possible with unified legislation. Because within the EU products have free 
movement, the acceptance of medicine in one member country basically means 
that it can also be brought to other countries. Therefore, working around the 
process patent in one country allowed similar products to be marketed 
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throughout the EU even though in other countries these products might have 
violated the product patents. It was possible to use process patents this way, 
because changing one part in the production process is relatively simple in 
comparison with changing the active ingredient of the medicine. So it was 
possible to get a product authorized, for example, in Finland and then based on 
the EU market regulations rather easily seek market authorization in the other 
EU countries. 
For the purpose of the study understanding legislation relating to basic patents 
is enough, as this is the main patent, which expiry enables generic competition 
in a large scale. However, as patenting is an important way for innovative 
medicines companies to protect their turnover, there are many other layers in 
patenting that are next presented to give an idea of the complexities involved in 
patent protection. As mentioned, currently basic patents in all industrial 
countries are product patents. Previously basic patents could have been process 
patents, but today process patents are one of the supplementary patent class 
that are used to provide additional protection for the products. Other types of 
supplementary patents are formulation patents, patents relating to salts and 
derivatives, polymorph patents, second indication inventions, metabolite 
patents, and dosage regimen patents. A basic idea of all of these is to extend the 
patent protection time of basic patent. Extension basically occurs because all of 
these supplementary patents are applied after the application of basic patent. 
This legislation on supplementary protection is generally homogeneous in 
Europe. (Mándi, 2003.) 
Further Unification of Patent Legislation and Supplementary Protection 
Certificates 
So currently all of the European countries have product patent systems in place 
and are unanimous in that sense. Also all product patents are 20-year for all 
pharmaceutical products except biotech. This is based on the World Trade 
Organization’s TRIPS Agreement (Trade-Related Aspects of Intellectual 
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Property Rights). The TRIPS agreement has been in place for all the EU 
countries as part of WTO since 1994 (Redwood, 2004).  
In addition to the patenting of substances and processes, in medicines the 
medical use of a known compound is also patentable under certain conditions. 
Sometimes an active ingredient can have other medical use than what it was 
originally developed and this type of patenting affects to this. The European 
Patent Convention (EPC) was held in 2000 to discuss these aspects. The decision 
was that only the first use is patentable. However, that decision still effectively 
allowed patentability of subsequent medical uses through creative patent 
drafting. EPC has been seen to strengthen the usage patents and increase the 
legal uncertainty. However, this situation was unified in 2007 when the updated 
version of EPC, known as EPC 2000, came into force eliminating in theory much 
legal uncertainty. (Roox, 2008.) 
Moreover, medicines usually have a possibility to seek industry specific 
extensions to normal patent times due to the nature of the business. Normally, 
patents are granted so that the developer could have time to get profits from 
markets to cover the expenses that were required to make the product. In 
pharmaceuticals, 20 year patent protection time is shortened because of the 
extensive testing required before the product can have market access. Also 
patenting usually needs to be done for the active ingredient early in the process 
of developing new medicines. All this takes time from exclusive market access 
and thus there are additional systems in place to extend the protection time 
after the normal patent protection period. In regard to this, Supplementary 
Protection Certificates (SPC) were introduced in the EU in 1992. SPC increase 
20-year patents by up to 5 years so that product would get 15 years of effective 
monopoly on the market. (Mándi, 2003; Redwood, 2004.) 
Data and Market Exclusivities 
Data protection and exclusivity as well as market exclusivity and the changes in 
them are another important thing affecting the position of generic medicines. 
Data exclusivity guarantees additional market protection for innovative 
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pharmaceuticals by protecting the data submitted by companies for the 
purposes of obtaining market approval. (Cullen, 2007.) Market exclusivity 
protects markets but enables the use of data and thus enables the development 
work on generic medicines.  
Major changes in data protection in pharmaceutical industry started in 1987, 
when 6/10-year data exclusivity regimes were introduced to biotech products 
(EGA, 2004). In 1995, 10-year data exclusivity was enforced in the EU to 
products adapting the centralized procedure to get the marketing authorization 
(Redwood, 2004). Marketing authorization will be discussed more in the next 
chapter.  
Final change to the current conditions happened in 2004 when the EU 
pharmaceutical legislation was amended with the directive 2004/27/EU for 
human medicines. This amendment included many provisions affecting the 
generic products and harmonization of the period of data exclusivity across the 
EU, which basically meant that Bolar-provision was also included in the 
European legislation. Accordingly the change happened 20 years after 
introducing Bolar-provision in the United States. Exclusivities varying between 
six to ten years were changed to eight years of data exclusivity plus two years of 
market exclusivity, adding another year for new indications authorized during 
the first eight years of data exclusivity. Usually, this is shortened to 8+2+(1) data 
exclusivity + market exclusivity. So in practice generic medicines market entry 
can happen in the earliest ten years after the original product but as the last two 
years is market exclusivity the generic entry after the end of the patent and 
exclusivity period is shortened (Mossialos et al., 2004, p. 247).  
Marketing Authorization 
Marketing authorization is needed in the EU to put the pharmaceutical on the 
market. Marketing authorization can be acquired in two ways: centralized 
procedure or community authorization and decentralized procedure or national 
authorization. The centralized procedure has been in place since 1995 with the 
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introduction of the European Medicine Evaluation Agency (EMEA) (Mossialos et 
al., 2004, chap. 4). However, because the data exclusivity for centrally 
authorized products was ten years, generic applications did not begin until 
2006 (European Commission, 2009, p. 116). Before 2006, the decentralized 
procedure was used to marketing authorization for the generic medicines. In 
this procedure, the applicant applied marketing authorization directly from one 
member state. If this was successful, the applicant sought to have other member 
states recognize the approval and grant their own marketing authorization. 
(Mossialos et al., 2004, chap. 4.) 
The effect that centralized procedure brought to obtaining marketing 
authorization was predictability and clarity. The time for getting marketing 
authorization from the centralized procedure through EMEA is structured. 
Within 210 days of submitting the application the results are ready (EMEA, 
2005). With the decentralized procedure, the variation was much higher. Also 
the procedure is now similar thorough out the EU giving equal opportunities for 
all the actors. 
Paediatric Extensions  
Paediatric Extensions or the Paediatric Regulation entered into force on January 
2007. This regulation is a series of obligations, incentives, and rewards aimed at 
medicines for children. Opinions are varying on their effect on the generic 
medicines markets for children. Due to recent introduction, which means that 
effects are not completely seen in the industry and that this is applicable to only 
a portion of the industry, these extensions will not be analyzed any further in 
this thesis. (Howard, 2008.) 
Summary of the Patent Regulation 
For the success factors’ analysis in generic medicines industry, it is seen that 
homogeneous patent protection including patenting, Supplementary Protection 
Certificates, data and market exclusivity as well as marketing authorization 
gives all the actors in the market similar environment and thus does not give 
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any comparative advantage. In addition to that, when thinking about the 
industry in the long run, the effect of extended patent protection of a single 
medicine is irrelevant to the overall success of the industry. Patent protection 
will eventually expire and enable generic competition. However, in the short 
term growth for the generic markets is seen to come from the patent expiries. 
This is indicated to be a major factor in generic medicines industry’s growth, but 
again the effect of this is similar to all of the actors in generic medicines 
industry. (European Commission, 2009, p. 38; Redwood, 2004).  
In other words, patent and IP regulation enables the generics medicines 
industry rather than decides its success. Major changes in the European 
legislation from the 1980s to this day have essentially simplified the process of 
getting generic medicines to the markets. This means that market access and 
market protection are predictable and thus business decision making for 
companies is simplified. This analysis can be formulated to another proposition 
about the industry dynamics. The proposition states that patent regulation is a 
necessary condition for the industry. 
Proposition 6: Patent regulation enables the generic medicines industry, but does 
not substantially influence its success. 
3.2.2 Promotion of Generic Medicines 
In addition to the changes in patent legislation, the changes in policies regarding 
generic promotion have been varying from country to country. This has varied 
even more than patent legislation and today there is still less uniformity in these 
policies between the countries than there is with the patent legislation. 
Promotion is one of the most important aspects affecting the position of the 
generics from country to country.  
In promotion related regulation and environment there are four main topics 
that will be discussed here (see Kjoenniksen, Lindbaek, & Granas, 2006; 
Redwood, 2004). The first area is generic prescribing, which means the 
possibility to prescribe using generic or International Non-proprietary Names 
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(INN). The second area is generic substitution, which means the possibility to 
change prescribed medicine to generic equivalent by the pharmacist. The third 
area is price regulation, under which reference price systems (RPS), 
reimbursements and patient co-payments are discussed. The fourth area is 
patient’s acceptance towards generic medicines.  
For the promotion of generic medicines, these points have different effects and 
legislative tools for governments are different for each point. Still, many times 
these aspects are used in parallel as they are somewhat overlapping. However, 
these tools do not have clear pan-European policies as will be seen next. The 
summary of the promotion related aspects within European countries is 
presented in Appendix 2. Appendix 2 is based on the data from Pharmaceutical 
Pricing and Reimbursement Information (PPRI) (Vogler, Espin, & Habl, 2009; 
Vogler et al., 2008). There have been three variations from this source: in the 
case of Iceland Martikainen and Rajaniemi (2002) was the source; in the case of 
Romania Kazakov (2007) provided data; and in the case of Switzerland Paris & 
Docteur (2007) provided information.  
Generic Prescribing 
Generic prescribing and other prescription guidelines have both varying 
policies between the European countries. From these two, generic prescribing is 
more important for generics industry’s performance. Other prescription 
guidelines relating to economic prescribing and use of medicines also have an 
effect but their role for the generics can be considered being secondary and only 
increasing the effects of generic prescribing (Vogler et al., 2008). 
Generic prescribing is a term relating to doctors’ possibility to write 
prescriptions with generic products. When allowed in the country, generic 
prescribing can be indicative or obligatory. Furthermore, generic prescribing 
most often happens with an international non-proprietary name (INN), which 
basically means that prescription is written to an active ingredient. Generic 
prescribing can also happen with a brand name, generic name, or with a 
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combination of any of these. There might also be differences of allowing generic 
prescribing in public and private sectors. (Vogler et al., 2008, chap. 3.5.4.) 
Generic Substitution 
Generic substitution means that pharmacists are able to substitute a prescribed 
branded product with a generic equivalent product. Substitution can be either 
to a different proprietary name product or to a product which is marketed 
under the international non-proprietary name. Policies are varying for generics 
substitution between the countries in Europe, but usually substitution needs at 
least an agreement from a prescribing doctor. (Mestre-Ferrandiz, 2003.) 
When country has allowed generic substitution and there is an agreement from 
the doctor, then the prescribing can either be indicative or obligatory. This is 
clearly the biggest and most significant difference between the countries 
allowing generic substitution. In indicative substitution, pharmacists are 
allowed to substitute, but in an obligatory system they are obliged. Especially in 
an obligatory system, doctors usually have the opportunity to deny generic 
substitution by indicating so in the prescription (Vogler et al., 2008). Generic 
substitution in most cases in Europe is related to the generic prescribing system 
being in place. Also substitution is in many cases combined with the reference 
price system, which will be discussed more in the next chapter. (Vogler et al., 
2008.) 
Generic Price Regulation and Reimbursement 
From four points discussed here under the generics promotion, price regulation 
related aspects are the most complex. However, they are in a sense the most 
important, because they have the most direct influence on the finances of the 
generic medicines industry. Complexity in the pricing regulation comes from 
two aspects, reference price systems (RPS) and reimbursements with patient 
co-payments, which have slightly different effect on generics position and on 
generics possible success.  
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To understand RPS, the concept of reimbursement must be explained. 
Reimbursement is the fraction of the actual medicine price that is paid by a third 
party payer. Third party payers include governments and insurance companies 
and the levels on which they pay differ from country to country. In addition to 
that, the part that is paid by the patient after the reimbursement is called 
patient co-payment. (Mestre-Ferrandiz, 2003.) 
In RPS, health authorities set a maximum reimbursement level for a given 
medicine. This level is called a reference price. Usually reference prices are not 
set at individual medicines directly, but medicines are categorized in groups 
based on similar or the same active ingredients, usage, dosage, or any 
combination of these. Reference prices are set for these groups. (Mestre-
Ferrandiz, 2003; Vogler et al., 2008.) 
When RPS is in use, a patient has possibility to choose to take a product that is 
under or exactly at reference price and in that case there will be no payment 
made by the patient. The total price of the medicine will be reimbursed. This 
makes RPS different from the traditional way of medicines purchase under the 
percentage systems, where the option for non-payment is usually not possible 
as patients pay the same percentage as co-payments regardless of the 
medicine’s original price. (Mestre-Ferrandiz, 2003.) 
The main objective of RPS is said to be that it increases price competition. In 
addition to that, it is said that RPS implicitly should increase generic 
penetration. Increasing generic penetration clearly indicates that the use of 
expensive products is cut down. This has been shown to be true at least in some 
cases (Aaserud et al., 2006). These are the main reasons why RPS is taken to use 
in an increasing number of European countries. The total number of countries 
in the EU that have the RPS in place is 19 after Finland adapted the system at the 
beginning of April 2009. This list is presented in Appendix 2. (Mestre-Ferrandiz, 
2003.) 
It is worth noting that RPSs vary by their principle of setting the reimbursable 
price between the countries. Usually a reference price is a function of the 
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cheapest medicine in a group, which in general is a generic medicine. As the 
reference price is a function of some cheaper products and as usually it is 
possible for a patient to get the cheapest product without paying anything, 
authority management for the system is needed. Products that have a price 
below the reference price tend to increase their price towards the reference 
price, which has a negative effect on the price competition. (Vogler et al., 2008.) 
General differences in RPS systems between the countries, for example the 
medicine groups of which RPS applies or the price setting functions, are not 
considered that significant. The most important aspects in the analysis of price 
policies at the European level are between the actual implementation of RPS. In 
addition, reimbursement levels and co-payments that are closely related to RPS 
are seen to have only secondary effects on the success of the generics. 
Patients’ Acceptance 
As mentioned patients’ acceptance is one of the principal factors for how rapidly 
the generics opportunity can be realized in practice and how successful of the 
previously presented promotion related legislation is (Redwood, 2004). This 
can be problematic since no regulation can affect patients’ acceptance directly, 
but patients’ acceptance can have a big effect on the success since their actions 
can limit the use of substitution. It is also patients’ decision of choosing the 
generic equivalent and allowing the substitution (Kjoenniksen et al., 2006). It is 
indicated that pharmacists and physicians are needed to provide additional 
information and support to increase the acceptance (Kjoenniksen et al., 2006). 
Media’s role in distributing information could also be important.  
Even though prescribing or substitution regulation has no direct way of 
affecting acceptance towards generic medicines, pricing regulation might have 
this. Kjoenniksen et al. (2006) indicates by referring to Lund-Jacobsen (1992) 
and to Andersson, Sonesson, Petzold, Carlsten, and Lonnroth (2005) that 
stronger financial incentives for patients could increase the acceptance. Even 
though patient’s acceptance is a complex area to analyze, the indication of it 
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being tied to the price makes it possible to analyze its effects through the pricing 
regulation.  
Summary of the Generic Promotion 
Generic medicines promotion is still typically decided on the national level, 
which is clearly different from the patent legislation. There are not many 
policies or even guidelines that are unified in Europe. This is one reason why 
promotion related aspects provide opportunities for generic medicines. Also as 
these aspects are decided on national level and they differ throughout Europe, 
there is a need for unified policies in Europe. This indicates that promotion 
regulation should experience more changes than patent regulation. Summary of 
the most relevant policies in the European countries are presented in 
Appendix 2.  
Of the aspects discussed above it is concluded that the most effect on the 
success of generics is achieved through price regulation. This is indicated by a 
few things. Patients’ acceptance is pretty closely related to financial benefits 
they expire when substituting to generic medicines. In addition to that, 
reference price system is in many cases the last step in the legislative process to 
promote generics. It is enforced after the substitution and prescribing is allowed 
before. Obviously, they all work in parallel and in theory the best results for the 
generics should be obtained if all three are enforced simultaneously. The 
influence of promotion legislation on the industry dynamics can be formulated 
to following propositions. 
Proposition 7: a) Promotion legislation affects to the success of the generic 
medicines industry. b) Among the promotion legislation, price regulation has 
single most effect on the success of the generic medicines industry.  
3.2.3 The Evolution of Institutional Environment 
In the European institutional environment changes that are the most interesting 
for the generic medicines industry are the changes regarding market 
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unification. Unified markets in general are more effective. On the other hand, 
differing policies between countries might be a source for comparative 
advantage and make a difference in performance. Unification of the European 
pharmaceutical markets started gaining respectable efforts in the late 1980s. In 
1985, gradually the EU (European Economic Community at the time) started 
evolving more and more towards its current state and the vision of the single 
European market became more and more clear. At the time, the vision was to 
create a single European market by the end of 1992, which also escalated 
changes affecting pharmaceutical industry. (Orzack, Kaitin, & Lasagna, 1992.) 
One obvious reason for such changes was the clear ineffectiveness of the multi-
state procedures. In consequence, 1992 Maastricht Treaty on European Union 
was approved. It entered into force on November 1st 1993 and the EU was 
officially founded. This gave the EU binding authority on some health care issues 
(Vogel, 1998). National governments remained in control of the health policy, 
including pharmaceutical policy. The EU did not get authority to decide on 
pricing methodology and this situation remains today. (Kanavos & Mossialos, 
1999.) 
Soon after 1992 another set of changes were proposed and those concretized in 
1993. 1993 the European Medicines Evaluation Agency (EMEA) was established 
and it started its work at the beginning of 1995 (Mossialos et al., 2004, p. 80; 
Kingham, Bogaert, & Eddy, 1994). This agency enabled the centralized approval 
procedure and a mutual recognition of national approval for medicines 
including generic ones with some exceptions (Kingham et al., 1994).  
Other changes that have definitely affected the position of the generics in the 
European level have been the enlargements of the EU. This includes the 1995 
enlargement to Finland, Sweden and Austria and the more recent enlargement 
to Central and Eastern European (CEE) countries and to Baltic states in 2004. 
The latest enlargement was in 2007 when Bulgaria and Romania joined the EU. 
Maybe the most important event was the enlargement to CEE and to Baltic, 
because the enlargement included most countries and there the promotion 
3 European Generic Medicines Industry 49 
legislation affecting generic medicines has been quite different from Western 
Europe (e.g. Kazakov, 2007). Even though they adapted a number of 
collaborative initiatives already from 1997 to update their regulation to match 
that of the EU, the change that the accession brought was substantial. The latest 
addition to their regulation was the implementation of 6-year data exclusivity 
and 5-year supplementary protection certificates in 2000 (Mossialos et al., 
2004, chap. 19). In addition to promotion, industry structures have been 
different due the centralized procedures in the Soviet systems (Mossialos et al., 
2004, chap. 14). At the same level as the enlargement of the EU among major 
institutional changes affecting the position of generic medicines is definitely the 
change to the common currency of euro in 1999. In conclusion, changes in the 
institutional environment are at the higher level and thus have mostly indirect 
effects on the industry. 
3.3 Economic Environment 
This chapter will have three parts. First part discusses the overall position of 
generic medicines in the world. Second part is about more detailed country level 
data in Europe. This part discusses the generic penetration in Europe. Third 
part discusses the economics of the industry from the payers’ perspective. It will 
have a focus on the expenditure on pharmaceuticals and provide information 
about the reasons for growing expenditure. There the rising research and 
development costs are an important factor. For calculation purposes currencies 
were exchanged to euro using the exchange rates presented in Appendix 1. 
3.3.1 Generic Medicines in the World  
Many reports indicate that worldwide generic medicines market will be 
experiencing quite a big growth in the coming years. The growth has been 
around 15% annually in the beginning half of the 2000s. IMS2 estimated 17% 
compound annual growth rate (CAGR) between 2000 and 2004 for generic 
                                                        
2 IMS Health is a private company providing proprietary data on health care 
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medicines sales (Hoffman, 2005). Datamonitor estimated the 14.8% CAGR for 
generics market value between 2003 and 2007 (Datamonitor, 2008a). This is 
expected to continue as both sources indicate similar numbers for the upcoming 
years. IMS estimates 10-15% yearly growth and Datamonitor 10.5% CAGR until 
2012.  
In absolute market values, generic medicines are a smaller business than 
original medicines. In Figure 7 the total world pharmaceutical market, which is 
valued around 450 billion euro, is divided into generic medicines and other 
medicines and to the regions of Europe and the Rest of the World (ROW). Other 
medicines in this case consist of original medicines and other than ethical 
generics, for example, meaning over-the-counter (OTC) medicines. Clearly the 
biggest part of the other segment is the original medicines. Furthermore, North-
America consists of clearly the largest part of ROW figures in both generics and 
others. Data is based on reports by Datamonitor (2008a, 2008b, 2008c, 2009) 
and calculations.  
 
Figure 7: Market Shares and Values (€ Billion) of Generic and Other Pharmaceuticals in Europe and Rest of the 
World (ROW), 2008 
 
ROW: Other  
pharmaceuticals;   
287 (63%)    ROW:  
Generics; 39 (8%)    
Europe: Other  
pharmaceuticals;   
108 (24%)    
Generics; 22 (5%)    
Europe:  
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There are many reasons for generic medicines to grow faster than original 
medicines. Expectations are also that this growth will continue. Many reasons 
are introduced in the literature. Some that are mentioned include economic 
growth in the regulated markets, demographic trends, and the need for cost 
control by payers. Moreover, the patent expiries of a large number of top-selling 
medicines both in the United States and Europe are one reason, why generic 
medicine markets are estimated to grow faster than original medicines. For 
example, Pfizer’s Lipitor (atorvastatin), the best selling single medicine in the 
world with the global sales over 9.2 billion Euros, will experience patent expiry 
in 2011 in the United States. (European Commission, 2009, pp. 29-38; Hoffman, 
2005; Pfizer, 2009.)  
Because generic medicines industry looks lucrative and is experiencing higher 
growth than pharmaceutical industry in general, innovative pharmaceutical 
companies are also becoming more and more interested in generic medicines. 
They are struggling with their traditional business models that depend highly 
on research and development (R&D) being able to bring new innovative 
medicines to the markets. R&D costs are going up and producing new medicines 
is becoming also other ways more challenging. That is why traditional 
companies are trying increasingly to protect their turnover by switching to 
generic medicines with different strategies and business models. (Karwal, 2009; 
Sheppard, 2009.)  
For the analysis of industry’s success, few notions need to be made. Patent 
expiries are one time occasions for industry growth and as new medicines are 
harder and harder to develop, these occasions are becoming rarer. Long term 
impact of these can thus be small. Moreover, demographic trends will be 
discussed later and payers’ influence is included in the previous Proposition 4. 
Therefore, the proposition from the economic environment can be formulated. 
Proposition 8: Good economic situation and economic growth have a positive 
effect to the success of the generic medicines industry.  
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3.3.2 Generic Penetration in Europe 
Maybe the most used measurement for overall generic medicines’ success is the 
generic penetration, which means the market share generics capture from the 
original medicines. Generic penetration can be measured in value and volume. 
In general market share in volume is higher than market share in value because 
of the lower overall unit price of the generic medicines. For the purpose of the 
study, market shares in value will be used as these present more clearly the 
turnover, which is associated with generic medicines. Therefore, the industry is 
better comparable to other industries as well as to public health care expenses. 
This can be formulated as a next proposition.  
Proposition 9: Penetration of the generic medicines tells about the overall success 
of the generic markets by comparing the industry with the traditional medicines 
industry. 
Figure 8 below presents the market shares of generic medicines by value in 
selected countries by European Federation of Pharmaceutical Industries and 
Associations (EFPIA, 2005-2009). EFPIA data is presented here as it offered the 
most complete list of countries and years of data about generics penetration. 
Other sources for generic market shares include EGA (EGA, 2007a), European 
Commission (European Commission, 2009, p. 62), and various research papers 
(e.g. Simoens & De Coster, 2006). These have published similar data with some 
differences in the values. Differences in the values occur due to the fact that the 
definition of generic medicines is different. A report by European Commission 
(2009, p. 62) indicates, for example, that in Finland figures differ because big 
Finnish companies of Orion and Leiras are counted as innovative original 
medicines companies even though they are also active in generic medicines.  
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Figure 8: Generic Medicines Market Share in Pharmaceutical Market Sales by Value (At Ex-Factory Prices) in 
Selected European Countries 2003-2007 (EFPIA, 2005-2009) 
As can be seen from Figure 8, penetration differs quite much between countries. 
Differences occur even though generics supporting has been on the rise for a 
few years already. Moreover, the EU has made efforts to unify the generic 
medicines markets and encourage the penetration of generics in Europe in an 
attempt to keep health care expenditure under control (European Commission, 
2009, p. 62). Based on mainly EFPIA data and secondly on the comparative 
analysis done between the other reports mentioned above European countries 
can be divided into three groups on the basis of the penetration. This division is 
presented in Table 5 below. 
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Table 5: Grouping of European Countries Based on the Development Phase of Their Generic Medicines 
Markets 
Group 
Developed 
Eastern European 
markets 
Developed 
Western European 
markets 
Developing 
Western European 
markets 
Generic medicines 
penetration by value 
around 40% 20-30% <20% 
Countries Croatia (non-EU)‡ 
Czech Republic* 
Hungary 
Latvia‡ 
Lithuania* 
Poland 
Romania 
Slovak Republic 
Slovenia 
Denmark 
Estonia*‡ 
Finland 
Germany 
Netherlands† 
The UK 
Austria 
Belgium 
France 
Greece 
Iceland 
Ireland 
Italy† 
Norway 
Portugal 
Spain 
Sweden 
Switzerland 
 
 
 
 
 
Notes: 
* = Classification based on EGA (2007) data rather than EFPIA data 
† = Classification based on Simoens & De Coster report (2006) rather than EFPIA data  
‡ = Not included in the final analysis 
 
First group consists of countries from CEE and Balkans, which in general are the 
most recent members of the EU. This group is labeled as Developed Eastern 
European markets. They have the highest penetrations of generic medicines 
among the European countries. Generally their share of generic medicines from 
the total market exceeds 40%. The second group of countries is group that is 
labeled as Developed Western European countries (see Simoens & De Coster, 
2006, p. 14). These countries in general have generic medicines market share of 
the total market in the vicinity of 20 to 30%. Even though Netherlands would 
not be included in this group by the very recent EFPIA figures, it is assigned 
here by the indication of Simoens and De Coster (2006). Last group of countries 
is formed from the rest of the Western European countries. This group is 
labeled as Developing Western European markets and those markets generally 
have a very low generic medicines penetration. Italy is assigned to this group on 
the basis of Simoens and De Coster (2006) even though the latest penetration 
figure is slightly above 20%.  
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3.3.3 Pharmaceutical Expenditure 
Rising Costs as the Sources of Expenditure Rise 
As has been brought up earlier, one of the main reasons why generic medicines 
have a big importance in Europe is the fact that expenditure on pharmaceuticals 
is in rise. Generics, when being cheaper alternatives to original medicines, are 
seen as one major way of fighting against the rising costs. Especially in Europe 
cutting costs is a priority because the majority of health care costs are paid by 
national governments.  
Reasons for overall pharmaceutical expenditure rise can be seen from the 
expense rises in pharmaceutical companies, which at least partly are 
transferred to the pharmaceutical prices and thus to pharmaceutical 
expenditure. Pharmaceutical companies’ relative expenses per new medicine 
rise because of two evident reasons. First the research and development (R&D) 
costs are on the rise and second the number of new medicines or new molecular 
entities (NME) being brought to the markets is on the decline. These trends can 
be observed from Figure 9 and Figure 10 (EFPIA, 2009).  
 
Figure 9: Pharmaceutical R&D Expenditure in Europe (Billion of National Currency Units), 1990-2007 
(Reproduced from EFPIA, 2009) 
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Figure 10: New Chemical or Biological Entities (1989-2008) (Reproduced from EFPIA, 2009) 
Together these trends mean that the cost per new molecule has risen 
substantially. Comprehensive analysis on the subject shows that the total costs 
of developing a new molecule have increased at an annual rate of 7.4% above 
general price inflation from 1987 to 2001 (DiMasi, Hansen, & Grabowski, 2003). 
In 2001, the total cost estimate is US$ 802 million. More recent analysis shows 
that this has risen to 1 318 US$ million in 2006 (DiMasi & Grabowski, 2007). 
There the annual growth rate is even over 10%. Clearly original medicines are 
becoming more and more expensive due to these cost increases.  
The unit price rise was discussed above as one reason for rising expenditure on 
pharmaceuticals in health care. Another reason is the rising use of 
pharmaceuticals. There the increasing number of elderly people is one 
important reason and this will be discussed more in Chapter 3.4.1 Demographic 
Factors.  
Pharmaceutical Expenditure Trends 
Because of the various policies in place and other measures that national 
governments have the radical change in costs is not so clearly seen in public 
expenditure. The trend is that costs are rising, but not as steeply as in R&D of 
medicines. According to World Bank Health, Nutrition and Population (HNP) 
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statistics3 in the euro area the public health expenditure as a share of total 
health expenditure rose from 75.7% in 2002 to 76.9% in 2006. Similarly the 
share of public health expenditure as a share of GDP rose slightly from 7.2% to 
7.5% from 2002 to 2006. This leads to the next proposition about the industry 
dynamics.  
Proposition 10: Rising pharmaceutical R&D costs increase the pharmaceutical 
prices and thus health care expenditures. 
Public health expenditure as a share of total health expenditure in 2006 for 
European countries as well as other selected regions is presented in Figure 11. 
The figure shows differences in Europe and even more in the World. Euro area 
has a clearly higher public expenditure share of the total health care 
expenditure than, for example, the World. This supports the fact that national 
governments have a reason to fight the rising costs in pharmaceuticals and 
therefore the rising public expenditure.  
                                                        
3 World Bank’s HNPStats. URL: http://go.worldbank.org/N2N84RDV00  
58 Ville Airo 
 
Figure 11: Public Health Expenditure as a Share of Total Health Expenditure in 2006 in European Countries 
and Various Other Regions (World Bank’s HNPStats) 
3.4 Social Environment 
3.4.1 Demographic Factors 
This chapter of the social environment will discuss only the effects of changing 
demographic factors on the generic medicines industry. According to Hoffman 
(2005) demographic trends affect the generics demand. The main demographic 
factor that is seen to have an impact on the success of the generic medicines is 
the aging population. This is because of two facts. Firstly the population in 
Europe, as well as in any other industrialized country in the world, is aging 
rapidly. Secondly older population consumes much more health care resources 
than any other younger age groups. For the aging population it has been 
estimated that the number of elderly citizens, meaning citizens aged 65 and 
over, will rise in the EU from 85 million in 2008 to 132 million in 2035 and to 
over 150 million in 2060. As a share of the total population, this means that the 
group of citizens over 65 in 2008 is approximately 17%, in 2035 it is 25%, and 
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in 2060 it is already 30%. Average estimated share of the elderly people in the 
EU and in selected member states are presented in Figure 12 below. The figure 
presents the cumulative share of the elderly people until indicated year. This 
means that, for example, the total share in 2035 is the sum of the bars of 2008 
and 2035. (Eurostat, 2008.) 
 
Figure 12: Estimated Cumulative Share of the People Aged over 65 in the EU and Selected European States, 
2008-2060 (Eurostat, 2008) 
There is substantial rise in the share of elderly people throughout the EU. 
Especially it seems that Eastern European countries are affected most by this 
demographic change. The whole change is made even more important because 
in health care the expenditure the EU member states currently spend on the 
citizens aged over 65 is between 30-40% of total health expenditure. The health 
care expenditure share is clearly higher than the share of the population. Part of 
this expenditure is obviously hospital expenses, treatments, and others, but also 
medicine expenditure is big. Radical rise in public health care expenditure as 
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population gets older is presented in Figure 13. (Economic Policy Committee, 
2001.) 
 
Figure 13: Age Profiles for Public Expenditure per Head on Health Care (Reproduced from Economic Policy 
Committee, 2001, p. 9) 
In addition to these, aging population also has other implications for the EU, for 
example, rising pension costs and lowering share of working age, which means 
lower production in case of every other factor remains at the status quo. 
However, in the context of pharmaceutical industry and generic medicines these 
do not have direct effect and are thus not that important for the overall 
performance. Demographic trends influencing the dynamics of the industry can 
be formulated to the next proposition. 
Proposition 11: The rising share of the elderly people increases the health care 
expenditures. 
3.5 Summary of the Generic Medicines Industry 
Above the industry was discussed under four broad topics. First area that was 
discussed was the operational environment. This analysis revealed the diverse 
playground surrounding this thesis’ core group of actors, the companies that 
have a marketing authorization for their generic prescription medicines in the 
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EU. Also the industry consolidation that has started was discussed and the 
effects this has had on the company population.  
After that the regulatory and institutional environment was discussed. To 
summarize major evolutionary changes in regulatory and institutional 
environment a timeline is presented in Figure 14. The figure is loosely adapted 
from EGA (2007b) and is filled with additional information that has been 
discussed above. The overall idea that Figure 14 shows is that institutional 
environment as well as patent legislation has unified in Europe in the last two 
decades.  
 
Figure 14: Timeline of the Major Changes in the European Regulatory and Institutional Environment Affecting 
Generic Medicines 
If looking at the regulatory environment, more closely one important difference 
can be seen that should have an effect on the success of the industry. The 
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difference is between patent and promotion regulation. In general, patent 
regulation is more homogenous in the EU and it is more clearly decided on the 
EU level. On the other hand, generic medicines promotion related aspects are 
still under the development to become unified in the EU. Currently these 
policies vary within the EU members quite much and are decided on the 
national level. So it seems that patent legislation has provided a lot of 
opportunities for generic medicines in the history. However, today promotion 
legislation provides most opportunities. Furthermore, these opportunities differ 
from country to country.  
Economic environment was discussed in the third part. This part showed that 
generic penetration, maybe the single most comprehensive indicator of the 
generic medicines overall success, varied between European countries. Eastern 
European countries had the highest penetration and Western European 
countries clearly had a group of countries with developed generic medicines 
markets and another group with developing markets.  
In the economic environment, the generic medicines position in the world was 
also discussed. Clearly, it is seen with generic medicines as well as with original 
medicines that the main markets are in the industrialized and wealthier 
countries. Also it was shown that due to the number of factors generic 
medicines had grown much faster than original medicines. This growth is also 
estimated to continue, which will introduce new companies to the markets. 
Moreover, the bulk of companies entering the markets are seen to be original 
medicine companies, which is seen as a major factor for accelerated mergers 
and acquisitions activity in the industry.  
Final issue that was discussed as a part of economic environment was the 
pharmaceutical expenditure. National governments in Europe are facing the 
problem of growth in health budgets and one reason for this is the growth in 
R&D costs. The number of new molecules is going down in original medicines 
industry at the same time as overall R&D expenses are going up. This 
substantially increases the unit price for a single new molecule, which obviously 
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raises the prices of medicines. In fighting the rising pharmaceutical expenditure 
public policies are in a key role in Europe. 
Under the social environment another reason for rising public health 
expenditure was discussed. This was the growing share of elderly people in 
Europe as well as in any other industrialized country. The current share of 17% 
of the population being older than 65 years of age is estimated to almost double 
to 30% in 2060. This is even more important for the health care than other 
industries, because at the age of 65 the public health expenditure rises 
considerably. 
All in all, multiple factors are seen affecting the industry. Relevant factors were 
formulated as propositions about the industry dynamics and are presented in 
Table 6. These propositions formulate one part of the overall industry dynamics. 
From these propositions total of six hypotheses can be formulated in addition to 
the first hypothesis formulated from the VoC theory. These will be presented 
below. 
Table 6: Propositions Made from the Generic Medicines Industry 
More specific propositions from the generic medicines context 
Proposition 4 The main influencers to the overall success of the generic medicines 
industry are the major payers of the health care costs at the 
government level. 
Proposition 5 Nation’s industry specific comparative advantages have an effect on the 
survival of the company population in that nation. Likewise, the survival 
of the company population manifests nation’s industry specific 
comparative advantages. 
Proposition 6 Patent regulation enables the generic medicines industry, but does not 
substantially influence its success. 
Proposition 7 a) Promotion legislation affects to the success of the generic medicines 
industry. b) Among the promotion legislation, price regulation has 
single most effect on the success of the generic medicines industry. 
Proposition 8 Good economic situation and economic growth have a positive effect to 
the success of the generic medicines industry. 
Proposition 9 Penetration of the generic medicines tells about the overall success of 
the generic markets by comparing the industry with the traditional 
medicines industry. 
Proposition 10 Rising pharmaceutical R&D costs increase the pharmaceutical prices 
and thus health care expenditures. 
Proposition 11 The rising share of the elderly people increases the health care 
expenditures. 
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Propositions 4 and 10 formulate a hypothesis addressing the role of public 
financing in health care. Due to the role of governments as payers and the rising 
pharmaceutical costs this hypothesis is formulated.  
Hypothesis 2: The high public share of the health care expenditure enhances the 
success of the industry. 
Proposition 5 formulates the next hypothesis that addresses the company 
population. The central role of the companies as actors in any economic system 
was also stressed in VoC. 
Hypothesis 3: The survival of the domestic generic medicines companies indicates 
suitable conditions for the whole industry. 
Propositions 6 and 7 formulate a hypothesis about the legislation of the 
industry. The importance of regulation and legislation for the industry is shown 
in the study. This hypothesis shifts the focus to the most relevant part of the 
regulation.  
Hypothesis 4: The enforcement of generic promotion by price regulation enhances 
the success of the industry. 
Proposition 8 formulates a hypothesis about the role of national income. In 
Europe with high income developed nations this hypothesis is especially 
relevant.  
Hypothesis 5: High national income enhances the success of the industry. 
Proposition 9 formulates a hypothesis about measuring success in the industry. 
Penetration by value as a measurement is useful as the figures are comparable 
to, for instance, other industries and national budgets.  
Hypothesis 6: The performance of the generic medicines industry can be measured 
by penetration. (High penetration is a sign of success of the industry). 
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Finally, Proposition 11 formulates a hypothesis about the role of demographics. 
Especially in Europe and other industrialized nations the importance of 
demographics for the development of the industry is substantial. 
Hypothesis 7: The high share of elderly people enhances the success of the 
industry. 
All of these hypotheses, the one presented previously and the six more closely 
industry related, are summarized in Figure 15. In Figure 15, the reasoning from 
the propositions to the hypotheses is also visualized. The hypotheses together 
build a framework for the analysis, which will be discussed more in Chapter 5 
Data and Analysis.  
 
Figure 15: Summary of the Hypotheses and the Reasoning from the Propositions to the Hypotheses 
Proposition 1
Proposition 2
Proposition 3
Proposition 4
Proposition 10
Proposition 5
Proposition 6
Proposition 7
Proposition 8
Proposition 9
Proposition 11
Proposition Hypothesis
The performance of the industry is enhanced in 
coordinated market economies.
The high public share of the health care expenditure 
enhances the success of the industry.
The survival of the domestic generic medicines 
companies indicates suitable conditions for the whole 
industry.
The enforcement of generic promotion by price 
regulation enhances the success of the industry.
High national income enhances the success of the 
industry.
The performance of the generic medicines industry 
can be measured by penetration. (High penetration is 
a sign of success of the industry).
The high share of elderly people enhances the 
success of the industry.
H1
H2
H3
H4
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H6
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4 Methodology: Fuzzy Set Qualitative Comparative Analysis 
The study seeks to utilize fuzzy set qualitative comparative analysis (fsQCA) 
(Ragin, 2008a, 2000) as the methodology for analyzing causal conditions and 
their dependencies among generic medicines companies’ performance in 
Europe. In the Varieties of Capitalism approach the use of set-theoretical 
methods was proposed. This was because of the problems with the traditional 
analysis methods and increased complexity in the research settings.  
FsQCA, which is also sometimes only referred to as fuzzy set analysis, is a rather 
new set-theoretic methodology to be used in social sciences. It is said that fsQCA 
is a middle path between quantitative and qualitative methods. These in this 
context are usually referred to as a case-oriented approach and as a variable-
oriented approach respectively. In addition to that, it is also said that fsQCA is 
not only a compromise between these two but it can actually go beyond the 
limitations of both (Ragin, 2008b). Limitations in the more traditional methods 
might include the shortage of data to make statistically significant analysis or 
the limitations to make a generalized conclusion from too detailed studies.  
Ragin’s work introduced fsQCA to social sciences at the beginning of the 2000s. 
However, even though fsQCA in social sciences has only been used for less than 
a decade the foundations for Ragin’s work and thus more generally for this type 
of analysis are much longer in the past. Fuzzy sets were first introduced in 1965 
by Lotfi A. Zadeh (1965) as an extension to classical sets. In classical sets, binary 
coding is used to formulate sets. Fuzzy sets introduced a continuous real unit 
interval of [0, 1] and thus allowed elements to have a membership of varying 
degree in a given set.  
The actual analysis of the relations between the sets has its foundation in an 
earlier work by Ragin. Ragin introduced qualitative comparative analysis (QCA) 
already in 1987 (Ragin, 1987). From QCA, the logical operations follow to the 
fsQCA. Original QCA was also based on the set theoretical framework, but with 
classical sets with the binary values. That is why in some of the resent studies it 
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is referred to as a crisp set qualitative comparative analysis (csQCA) to 
distinguish it from other types of QCA such as fsQCA (see generally Wagemann, 
2009). FsQCA is a part of set-theoretical methodology that allows as well as 
requires different approach from some of the more conventional data analysis 
methods (Fiss, 2007; Pajunen, 2008; cf. Järvinen, Lamberg, Murmann, & Ojala, 
2009). In fsQCA Boolean algebra is used to analyze combinations of sets. 
Traditional statistical methods, procedures, tests, and scores cannot be directly 
utilized in fsQCA.  
After this brief introduction, fuzzy sets, QCA, and the combination of them, 
fsQCA, will be discussed more closely. Detailed description is in place since this 
methodology has not been used in that many studies yet. The fsQCA will be the 
third and final part of the theoretical and empirical body of this thesis. 
4.1 Fuzzy Sets 
The idea of fuzzy sets is pretty simple and is well documented in various books 
and papers after Zadeh’s introduction (Zadeh, 1965). Fuzzy sets allow elements 
in a set to have the degrees of membership in a given set. In fuzzy sets the 
membership of an element in a set is valued to the real unit interval from zero to 
one or with the mathematical notion [0, 1]. The score of one means that an 
element is fully-in a set and value zero means that an element is fully-out of a 
set. In crisp sets, the way in which classical bivalent sets are called in social 
science (e.g. Wagemann, 2009), the only available values are zero and one. This 
opens up much more possibilities to analyze membership in a particular set 
than crisp sets offer.  
Another important in fuzzy sets is the score of 0.5. This indicates the crossover 
point with the maximum ambiguity of the membership in the set. In general, 
scores in the open ended interval of (0, 0.5) are said to be more out of the set 
than in the set and scores in the open ended interval of (0.5, 1) are said to be 
more in the set than out of the set. All of the variables that are used to construct 
the sets are needed to transform into this total interval of [0, 1]. 
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The process of transforming variables to sets is called calibration. The 
calibration process presents one superiority quality of fuzzy sets in illustrating 
things: irrelevant variation can be eliminated from the sets. In simple terms, this 
means that zero value in the ordinal scheme does not need to mean zero 
membership. Other membership scores are also set according to the definitions 
of the researcher by focusing most on the specifications of full membership and 
full non-membership, as well as the specification of fuzzy set score of 0.5. This 
implies that in certain analyses fuzzy sets can be more efficient than crisp sets. 
Calibration will be discussed later as a part of illustration of fsQCA itself.  
Zadeh’s work was at first used mainly in technical sciences such as in the 
control theory. It was not until the 80s when fuzzy sets were introduced to 
social sciences by Smithson (1987). However, Smithson introduced only the 
construction of the sets. The in-depth analysis of fuzzy sets as it is used today 
was not introduced in this context. However, in the same year Ragin (1987) 
introduced the predecessor methodology for analyzing fuzzy sets known as the 
qualitative comparative analysis (QCA). The next chapter will discuss this. 
4.2 Qualitative Comparative Analysis (QCA) 
Second part constructing fsQCA is qualitative comparative analysis (QCA) 
(Ragin, 1987). Building on this Ragin’s seminal work different comparative case 
analysis techniques have been developed. Today fsQCA is one of the most well 
known of these techniques. Some of the other better-known techniques in this 
field include multi-value QCA (mvQCA) (e.g. Cronqvist & Berg-Schlosser, 2009) 
and temporal QCA (TQCA) (e.g. Caren & Panofsky, 2005). (Rihoux, 2006.) This 
chapter will discuss the basics of QCA and then build on that and the traditional 
fuzzy set theory the combination of these called fsQCA.  
QCA was first introduced as a method of formalizing and extending traditional 
comparative case-study methodology (Ragin, 2000, p. 120). In case studies, the 
problem is that there are very few data points that usually are not enough to do 
statistically valid analysis. QCA is designed to overcome this problem by 
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introducing tools for comparing cases as the configurations of set memberships 
(Ragin, 2000). Because QCA operates in sets, operations are based on the 
variations of Boolean algebra, rather than linear algebra (Ragin, 2000, p. 121). 
In fsQCA, the algebra is called fuzzy algebra but it is analogous to Boolean 
algebra in its operations (Wagemann, 2009). This means that operations that 
can be used in QCA of any kind are especially negation, logical and, and logical 
or (e.g. Pajunen, 2008).  
Negation is basically the opposite of the original value and in QCA it can be 
presented with the formula 
 
Here A is the membership in the original set and the tilde sign “~” is used to 
present the negation. Subscript “i” indicates the “ith” case.  
Logical and is used in combining two or more sets. It is more commonly known 
as set intersection. In fuzzy sets logical and is obtained by getting the minimum 
membership score of each case in sets that are combined. Logical or is also used 
in combining two or more sets. This is more commonly known as the union. 
Logical or uses the maximum membership score of each case in sets that are 
combined. 
The idea of QCA is to make comparisons between causal conditions in included 
cases to see if their presence or absence has analytical interest for the presence 
of the outcome. This means that constructing a data set for the QCA requires a 
construction of the selected number of causal conditions or factors and the 
construction of one outcome. Analogy to the statistical analysis, if it is necessary 
to make, is that causal conditions are independent variables and an outcome is a 
dependent variable.  
In social sciences, the research usually begins with an outcome and its 
explanation (Ragin, 2000, p. 130). That is why the outcome for the analysis 
should be set early on. Then to explain this outcome researcher should identify 
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a proper number of causal conditions. The question is what the proper number 
of causal conditions is. Obviously restricting for identifying these conditions is 
the amount of data from which causal conditions can be constructed. This is 
similar to any statistical analysis. Also there should be no causal conditions 
identified that are similar to all cases in the analysis. If the condition identified is 
the same in all of the cases, it will obviously be present in the solution as it is a 
necessary condition for a case to exit. 
Moreover, Marx (2006) has studied the QCA setting with random data matrixes. 
He finds out in his analysis a benchmark table that assesses the probability to 
find a model with a given number of cases and causal conditions. He, for 
example, has found out that at least 16 cases should be used when using six 
causal conditions. This is because, with six factors when cases fall below 16 
there is a high change that random data will generate results, which means that 
there is a change that results are not valid. In his analysis five conditions would 
need 13 cases and seven conditions would need 27 cases. This analysis points 
some direction to the maximum number of causal conditions for a given number 
of cases.  
Tradition in the field has been that the number of causal conditions ranges from 
six to eight. Some practical reasons for this are that a smaller number of 
conditions would provide too simple solutions. This means that essential 
information might be required to generalize too much. On the other hand, more 
than eight conditions would generate too complex solutions and it would be 
hard to draw any conclusions from those. (Ragin & Rihoux, 2008, p. 28.) In the 
end, identified causal conditions give different combinations for causal 
conditions according to formula 2k, where k is the number of identified causal 
conditions. Formula comes from the fact that each condition can either be 
present or absent in the actual solution. 
The ultimate objective in QCA is to identify different causal combinations 
leading to similar outcomes. This is called causal complexity (see Ragin, 1987; 
Ragin & Sonnett, 2004). As a more developed version of QCA, fsQCA is especially 
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suitable for analyzing causal complexity as it provides means to analyze even 
more complex situations. However, it also creates more restrictions for 
identifying causal combinations or results. FsQCA will be discussed in the next 
chapter.  
4.3 Fuzzy Set Qualitative Comparative Analysis (fsQCA) 
4.3.1 Set Theoretical Properties of fsQCA 
In combination of previously discussed fuzzy sets and QCA, Ragin formulated 
the fsQCA methodology (Ragin, 2000, 2008a). It was introduced as a 
methodology for social science. Since its introduction, it has been gaining more 
and more interest among researchers from various fields. At first fsQCA was 
especially adapted to politics research (e.g. Epstein, Duerr, Kenworthy, & Ragin, 
2008; Stokke, 2004). Very recently methodology has been also adapted to 
management and business research and it is gaining more and more interest in 
this field also (e.g. Järvinen et al., 2009; Pajunen, 2008; Fiss, 2008).  
The reason why fsQCA is adapted to research is that there are clear benefits of 
using fsQCA. First benefit is that there is the possibility to conduct data analysis 
with fewer data points than with more traditional methods such as regression 
analysis. Second benefit is the possibility to conduct more complex analysis and 
thus obtain results from more complex phenomena. 
The idea in fsQCA is to explain a certain outcome with different causal 
conditions with QCA methodology, but replacing binary sets with fuzzy sets. 
However, it should be noted that crisp sets can also be used in parallel to fuzzy 
set as they can be considered a special case of a fuzzy set. All the values are 
calibrated to the closed real interval of [0, 1] to form fuzzy sets. As stated before, 
important values in setting or calibrating fuzzy sets are full non-membership 
with the score of 0, full membership with the score of 1, and maximum 
ambiguity (fuzziness) of the membership with the score of 0.5. When calibrating 
these three points, they need to be qualitatively anchored. It is required for the 
researcher to present a rationale for these points. Other values are 
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quantitatively assigned and thus fsQCA actually is able to combine qualitative 
and quantitative assessment (Ragin, 2008a).  
In calibrating fuzzy sets scores for fsQCA the interval [0,1] can be either set as 
continuous or it can be divided equally into a number of classes. For example, a 
three-value fuzzy set adds crisp set with one class that is of value 0.5. The idea 
of using these classifications is that they give qualitative anchor points for 
quantitative codings. Some of these are presented among others by Ragin 
(2008a, 2008c). Even though the fuzzy sets that are not continuous might seem 
similar to ordinal scales it is not in the context of fuzzy sets. In ordinal scheme, 
values are set into the set by simply based on their rank order. In fsQCA, this 
ordinal ranking is only first part of calibration. In second phase fuzzy sets are 
made distinct by the researcher’s conceptualization of the set. This was 
discussed above. (Ragin, 2008a.)  
Subset relation is the key set theoretic relation when studying causal 
complexity. Ragin states that if cases that share several causally relevant 
conditions uniformly exhibit the same outcome, means this that these cases 
constitute a subset of instances of the outcome (Ragin, 2000, 2008a). This 
subset relation means that a specific combination of causally relevant 
conditions may be interpreted as sufficient for the outcome. There are two key 
set-theoretical definitions that are important for causal conclusions in the fsQCA 
and sufficiency is the first of these. There could be different combinations that 
display the outcome. These all may be interpreted as sufficient for the outcome. 
Like in the real world there is possibility for having different combinations that 
result in the same outcome.  
By definition, sufficiency implies that the causal condition X is a subset of the 
outcome Y. This means that for all cases outcome Y gets membership scores 
greater than or equal to causal condition X: 
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Another set-theoretical definition for fsQCA is necessity. In general necessary 
conditions are important to both social theory in general and therefore also to 
the fsQCA. By definition, theoretically relevant causal condition is necessary if it 
is present in all instances of an outcome. In fsQCA, the causal factor X is 
necessary if the outcome Y can be considered a subset of the causal condition X. 
The outcome Y can be considered a subset of the causal condition X if fuzzy 
membership scores of the causal condition X are greater than or equal to the 
scores of the outcome Y for all cases: 
 
Because of the fundamentally bivariate nature of the hypotheses about 
necessary and sufficient causation, the whole analysis is bivariate. This means 
that fsQCA does not suffer from a small-N or degrees of freedom problems, 
which are common to multivariate regression methods and therefore with 
fsQCA the statistical significance can be reached with a modest number of cases 
(Katz, Vom Hau, & Mahoney, 2005). The actual analysis of fsQCA closely follows 
the procedures described already in the original QCA (Ragin, 1987). The next 
chapter will discuss these practicalities in more detail.  
4.3.2 Conducting fsQCA 
Presently fsQCA should be conducted using the truth table algorithm that was 
introduced by Ragin (2008a). Previously there has been another algorithm for 
conducting fsQCA. The inclusion algorithm is the older one and it was presented 
at the same time as fsQCA by Ragin (2000). This has been applied in several 
studies (see Katz et al., 2005; Pajunen, 2008), but currently inclusion algorithm 
is under further development and it is seen that at the moment the truth table 
algorithm is superior to the inclusion algorithm. The inclusion algorithm is 
being developed to be more robust and to make it more consistent with the 
truth table analysis, but until the new release inclusion algorithm should not be 
used for fsQCA. The thesis will also employ the truth table algorithm meaning 
that the study is mainly of sufficient causation. (Ragin, 2008c.)  
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The actual analysis when using the truth table algorithm will be explained next 
(for more detailed discussion, see Ragin, 2008a). The analysis begins with 
selecting k number of causal conditions to explain one outcome. These causal 
conditions together construct a multidimensional vector space with 2k corners. 
Each of these corners represents one line in the truth table. In addition to that, a 
case is regarded as a member of the corner when it has a fuzzy set membership 
score of more than 0.5 in that corner.  
After the table is constructed the researcher should assess each configuration, 
meaning each the row, on two aspects. First researcher assesses if the 
configuration is relevant. If it indeed is, then the configuration needs to be 
assessed on its sufficiency for the outcome in question. In practice, relevant 
configurations are distinguished with the empirical evidence. For a small 
number of cases, adequate empirical evidence to support the idea that a 
configuration is relevant can be considered one case. Those configurations that 
have membership frequencies below the threshold are called logical remainders 
and are removed from the table, because they lack adequate empirical evidence.  
On the remaining configurations, the evaluation whether the configuration is 
sufficient or not for the specific outcome needs to be done. This is evaluated 
with the consistency measurement. Consistency is defined as follows (Ragin, 
2008a, 2006). 
 
where Xi represents membership scores in a combination of causal conditions, 
and Yi represents membership scores in the outcome. “Min” means the selection 
of the lower of two values. Consistency score can be from zero to one, where 
one indicates full consistency. Full consistency means that all cases are subsets 
of the outcome. For consistency scores Ragin (2008a) recommends that a cut-off 
value of 0.85 or higher is used. In addition to that, he states that it should not be 
less than 0.75 in any case, since scores between 0 and 0.75 indicate substantial 
inconsistency. Based on the scores and their analysis the column termed as 
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“outcome” at the analysis software is encoded in consistent and inconsistent 
cases. Software will be discussed more in the next chapter. 
After all this data is imputed to the software, the Quine-McCluskey algorithm of 
QCA, which included in the software, is used to find the final solution. This gives 
three solutions. In the language of Ragin and Sonnett (2004) two original 
solutions are called the “complex” and “parsimonious” solutions. Complex 
solution is more detailed and includes more rows than parsimonious. 
Parsimonious solution is generated by re-analyzing the truth table with the 
remainder rows, or rows with combinations lacking good instances, set to “don’t 
care” (Ragin, 2008a).  
The third solution is called “intermediate” solution. Intermediate solution can 
be obtained by providing additional simplifying assumptions in the course of 
analysis. A researched might have a reason to provide these assumptions if 
complex solutions have a change to be too complex. (Fiss, 2008.) However, by 
providing simplifying assumptions, the generalization of the results becomes 
harder and thus the use of intermediate solutions should be assessed separately 
for each study.  
When the solutions are obtained, they still need to be analyzed more closely. To 
help this two description measures exists. These are consistency and coverage. 
Consistency measures the accuracy of a solution and is analogous to the 
configuration consistency presented above. In analyzing results, consistency 
score should be assessed before assessing the coverage. There is no reason in 
analyzing the coverage of the solution that is not a consistent subset of the 
outcome (Ragin, 2006).  
After establishing the consistency, coverage, which measures the generality of 
the solution, needs to be assessed. Coverage describes the amount to which 
solution covers the outcome or in other words the importance of a causal 
combination in achieving the outcome (Fiss, 2008). It is calculated using the 
formula: 
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Values are between zero and one and the values close to one imply high 
coverage.  
There is often a trade-off between consistency and coverage. High consistency 
could lead to low coverage and vice versa. That is why it is important to 
understand the differences between these two when analyzing the results. More 
interesting results therefore have high consistency scores. Their coverage 
scores only imply the empirical importance. In practice this means that in 
studies where there are a small number of cases and a lot of causal 
combinations found the coverage of a single combination is usually low. (Ragin, 
2006.) 
4.4 Software 
The actual analysis is conducted using the software package intended for fsQCA 
(Ragin, Drass, & Davey, 2009)4. This software has the truth table algorithm 
implemented in it with all the above described features. More detailed 
discussion about the practicalities in the use of the software is presented by 
Ragin (2008c).  
One thing that is notable for using software is the fact that it has a limitation of 
analyzing cases with memberships of exactly 0.5. This is because these 
membership scores actually have membership in the multiple corners of the 
constructed vector space. Ragin (2008d) recommends avoiding the use of 0.5 
membership score for causal conditions. Fiss (2008) proposes another solution 
to overcome this problem. He proposes that adding a constant of 0.001 to all 
                                                        
4 fs/QCA 2.5 software Ragin, C. C., Drass, K. A., & Davey, S. (2009). Tucson, Arizona: Department 
of Sociology, University of Arizona. The program can be downloaded from the website 
www.fsqca.com (Accessed 19.2.2010). 
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membership scores below 1 eliminates the problem, but does not change the 
results significantly.  
4.5 Applicability to the Study 
As a methodology fsQCA is nowhere near finished and criticism on its usage in 
social sciences is also available (e.g. Lee, 2008). Regardless of that, this 
methodology is adapted here as it is seen that it provides the most 
comprehensive analysis on the causal dependencies in generic medicines 
industry in Europe. Therefore, the results should also be the most usable.  
Few clear reasons for choosing fsQCA can be found. First of all the methodology 
supports the future research proposals for the Varieties of Capitalism theory as 
discussed earlier. Secondly, the study has the limitation with the number of 
cases available for analysis, which makes standard statistical analysis a difficult 
task. On the other hand, analyzing every country qualitatively as separate cases 
would be a too difficult and complex task.. In addition, as fsQCA is a relatively 
new methodology studying its applicability to this context provides important 
information about its usability. 
In comparison to other mentioned QCA variations such as crisp set QCA and 
multi-value QCA, fsQCA stands out by being able to handle the most complex 
situations (Rihoux, 2006). The chosen empirical data of generic medicines 
industry is very complex and therefore requires a complex methodology to 
produce robust results. FsQCA is seen to fit this setting best and thus it builds 
the third part of the theoretical and empirical body of this thesis. In the next 
chapter, all of these parts will be combined and the analysis setting will be 
discussed.  
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5 Data and Analysis 
This chapter elaborates the used data and the analysis of the generic medicines 
industry’s success factors in Europe. First the overview of the analysis setting 
with data and calibration methods is presented. Then used fuzzy sets are 
presented case by case. Reliability and validity will also be assessed case by 
case.  
5.1 Overview of the Factors 
In the study, the assessment of reliability and validity follows the positivist 
tradition (e.g. Behling, 1980; Cook & Campbell, 1979) in the way explained by 
Gibbert, Ruigrok and Wicki (2008). In this setting, the assessment is divided into 
internal validity, construct validity, external validity, and reliability. Internal 
validity addresses the causal relationships between factors and results and 
therefore in the study is mostly associated with choosing the factors. Construct 
validity addresses operationalization of relevant concepts. In the study, this 
mostly refers to the conceptualization of chosen factors and that those 
represent what they are said to represent. External validity refers to 
generalizability to other context. Finally, reliability refers to the absence of 
random error in sources and methods and enabling the research to be 
conducted again using the same path. All of these aspects will be assessed in 
parallel of explaining the analysis.  
The analysis will be conducted with six causal conditions. There are two reasons 
for this. First, the more theoretical reasons are that it is in line with the 
practicalities proposed for QCA (Marx, 2006). Marx’s analysis proposes the 
maximum number of causal conditions for the thesis to be six with available 24 
cases. Second reason for choosing six conditions is the more practical. Seven 
hypotheses were formulated from the propositions addressing the industry 
dynamics (see Chapters 2 and 3 and Figure 15 at p. 65). From these one 
transfers to outcome and six to the causal conditions. It is seen that with six 
conditions explaining the outcome it is possible to include the most relevant 
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aspects of the industry and, furthermore, nothing irrelevant needs to be 
included. Six causal conditions are also in line with the practicalities in the 
recent fsQCA studies (Ragin & Rihoux, 2008, p. 28). In practice, fuzzy sets are 
used in operationalizing the hypotheses. All the fuzzy sets with the hypotheses 
and the measurements used to construct the fuzzy sets are presented in Table 7. 
The reasoning for operationalization and measurement will be further 
elaborated under the chapters of each fuzzy set. 
Table 7: Summary of the Constructed Fuzzy Sets 
Category Hypothesis Measurement Abbr. 
Fuzzy Set (of 
countries with) 
Outcome H6: The performance of the 
generic medicines industry 
can be measured by 
penetration. (High 
penetration is a sign of 
success of the industry). 
Penetration of the 
generic medicines 
in value 
PEN Successful 
generic 
medicines 
industry 
Causal 
Conditions 
H3: The survival of the 
domestic generic medicines 
companies indicates 
suitable conditions for the 
whole industry. 
Survival rate of the 
domestic 
companies 
SUR Competitive 
domestic generic 
medicines 
industry 
H2: The high public share 
of the health care 
expenditure enhances the 
success of the industry. 
Share of public 
health expenditure 
of total health 
expenditure 
PHE Publicly financed 
health system 
H5: High national income 
enhances the success of 
the industry. 
GNI per capita GNI High national 
income 
H7: The high share of 
elderly people enhances 
the success of the industry. 
Share of the 
population over 65 
years 
O65 High share of 
elderly people 
H1: The performance of the 
industry is enhanced in 
coordinated market 
economies. 
Level of 
coordination in the 
capitalist system 
according to VoC 
COO Coordinated 
market economy 
H4: The enforcement of 
generic promotion by price 
regulation enhances the 
success of the industry. 
Presence of the 
reference price 
system 
RPS Established 
generic 
medicines 
promotion 
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As mentioned, the thesis is able to use 24 European countries as cases for the 
analysis. Case countries are presented in Appendix 3. Furthermore, the analysis 
is based on current conditions, which means that data is from the years 2007 
and 2008 in most of the cases. These were the most recent years of which 
comprehensive data was available. 
When looking at calibration procedures in the recent studies that have 
employed fsQCA (e.g. Fiss, 2008; Järvinen et al., 2009; Pajunen, 2008), it can be 
seen that there are no standards for calibration. The number of categories for 
fuzzy set calibration as well as the method of calibration to continuous fuzzy 
sets differs. However, Ragin (2008b) recently presented two distinct methods 
for calibration: the direct and the indirect method of calibration. The thesis will 
apply both of these methods for calibration of different fuzzy sets.  
Ragin (2008b) describes the procedure of both of the calibration methods in 
detail. In the direct method the transforming of variables needs three anchor 
points of full membership, full non-membership, and the crossover point of 0.5. 
After deciding on these the first step is to convert variables in to metric of log 
odds. For example, in this method the full membership with set membership 
scores ≥0.95 get the log odds of membership ≥3.0 and full non-membership 
with set membership scores ≤0.05 get the log odds of membership ≤-3.0.  
After the log odds transformation the membership scores are calculated using 
the formula 
 
In the formula, exponentiated log odds are divided by the unity plus the 
exponentiated log odds to obtain the degree of membership (Fiss, 2008). Ragin 
(2008b) notes that his procedures are mathematically incapable of producing 
set membership scores of exactly 1.0 or 0.0. That is why above, for instance, full 
membership score is already indicated with the value 0.95. According to Ragin, 
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the membership scores of 1.0 and 0.0 would correspond to infinites for the log 
odds.  
Even though the direct method has some limitations, it is indicated to be a 
superior method (Fiss, 2008; Ragin, 2008b). Fiss (2008) states the advantage 
being that it converts any interval variable into a set by using a metric that is 
symmetric around zero and has no floor or ceiling. In addition to that, fuzzy sets 
range from 0 to 1 as well as are tied to the thresholds of full membership, full 
non-membership, and the crossover point. Ragin (2008b) also estimates this 
procedure to produce results that are consistent with the conceptualization of 
degree of set membership. 
Due the limitation in data not all the set can be constructed in the thesis by the 
direct method. The indirect method proposed by Ragin (2008b) is therefore also 
applied. This method relies on the broad grouping of the cases. Ragin uses the 
grouping to six categories. Those categories and qualitative anchors are: 1 fully 
in, 0.8 mostly but not fully in, 0.6 more or less in, 0.4 more or less out, 0.2 mostly 
but not fully out, and 0 fully out. Notable here is that three important thresholds 
do not need to be directly defined with external criteria. Especially the score 0.5 
is missing. So if finding qualitative anchors is problematic, the indirect method 
should be used.  
After the grouping of the cases, the indirect method uses the original data as the 
independent variable and the qualitative codings as the dependent variable to 
estimate the predicted set memberships. Ragin points out that this procedure 
should be conducted with a fractional logit model. This is implemented in 
STATA5 in the FRACPOLY procedure (see more detailed discussion in Ragin, 
2008b), which is indicated to be the simplest way to construct this 
transformation. Therefore, this procedure will be employed here, where 
applicable.  
                                                        
5 STATA is a data analysis and statistical software from StataCorp LP, College Station, Texas 
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There are three reasons why methods proposed by Ragin (2008b) are adapted 
in this thesis. First, these are the most recent proposals for calibration. Second, 
they have already been employed in studies and thus at least partly validated. 
Fiss (2008) has recently used the direct method of calibration in his study. 
Third, the direct method is included in the latest version of fs/QCA (2.5) to 
automate the calibration after setting three threshold values6.  
The above presented reasoning addresses the reliability in the study. The use of 
methods that have been studied and validated previously reduces the random 
error that emerges from them. In that regard, the study reaches the required 
reliability for the methods. Next the chosen method of calibration as well as the 
used data will be explained for each constructed fuzzy set. 
5.2 Outcome Factor 
5.2.1 Successful Generic Medicines Industry (PEN) 
The chosen outcome factor is the fuzzy set of countries with successful generic 
medicines industry. It is abbreviated as PEN based on the generic medicines 
penetration, which is the data it was constructed from. PEN is chosen as the 
outcome factor because it is seen to describe the overall success of the industry 
in the country comprehensively. The value of the penetration measurement is 
indicated by the industry analysis and expressed in Proposition 9.  
For the analysis PEN uses European Federation of Pharmaceutical Industries 
and Associations (EFPIA) data set for generic medicines market share by the 
value in a case country in 2007. This data can be extracted from their yearly 
publication of The Pharmaceutical Industry in Figures7 (EFPIA, 2009). This data 
set covers 21 cases. Due the data set limitation, Czech Republic and Lithuania 
are added from European Generic medicines Association (EGA) data set from 
                                                        
6 Method can be found from the “Compute” -menu under the “Calibrate” -procedure 
7 Available at EFPIA website. URL: www.efpia.eu  
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20048. In addition, Hungary is added from EFPIA (2007) data set that covers the 
year 2005, because it has not been present in the more recent data sets.  
There are differences in the penetration data from various data providers. 
Relevant penetration data is provided among others EFPIA, EGA, and European 
commission. Many are based on some form of IMS data, which is not publicly 
available. Differences in the data sets come from definitions that they use. 
Nonetheless, EFPIA is chosen as the main data set because it covers the most 
case countries and has also published accurate numbers rather than just bar 
charts, from where only data estimates could have been extracted. Based on this 
reasoning PEN reaches the construct validity as well as the reliability required 
for the study. For the construct validity, the theory indicates that penetration is 
reasonable measurement for success and based on that PEN is able to 
conceptualize that. For the reliability assessment it can be argued that the 
random error is minimized by using the EFPIA data in a way explained above.  
This data is encoded in fuzzy sets using the indirect method. A case is coded to 
be fully out of the set if the penetration is below 10%. This classification is used 
by EGA in one of their reports to classify the countries with the worst generics 
markets (EGA, 2005). Same report classifies the best markets to above 40%. 
Here to get the score is lowered to 30% because in general EGA has slightly 
higher penetration figures and also 30% penetration is still well above the 
median penetration of about 20%. Therefore, with 30% penetration a case can 
be considered to be fully in the set of successful generic medicines industry. As a 
result qualitative coding uses the following six categories: Over 30%-
penetration scores 1; over 25% scores 0.8; over 20% scores 0.6; over 15% 
scores 0.4; over 10% scores 0.2; and 10% and below scores 0. After that, in the 
way described above, the interval-scale penetration data and qualitatively 
coded groupings are processed in STATA, which gives the predicted set 
membership scores that will be used in the analysis.  
                                                        
8 Available at EGA website. URL: www.egagenerics.com  
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5.3 Causal Conditions 
5.3.1 Competitive Domestic Generic Medicines Industry (SUR) 
First causal condition is a fuzzy set of countries with competitive domestic 
generic medicines industry. It is abbreviated as SUR, because of the used raw 
data of survival rate of the companies in a given country. This causal condition 
reflects the effects that domestic companies’ performance has on the success of 
the industry. The density analysis of the company population and Proposition 5 
support the use of this causal condition.  
SUR data is based on GloStra generic medicines companies’ database9. This 
database is conducted as part of GloStra research on generic medicines industry 
in Europe. Company data for this database was originally extracted from a 
number of sources. Main sources were the member organizations of EGA, which 
were able to track down on the yearly basis from the Internet Archive Wayback 
Machine10. Other major source for company information was the Lexis-Nexis 
newsfeed, which was partly processed with custom made software. This 
information was supplemented from the company websites. After the 
companies were identified, the database was added with the incorporation 
dates as well as the exit dates of applicable companies. Major source for this 
data was AMADEUS database11, which is not publicly available. In addition, at 
this stage company websites were used to fill the data gaps. The GloStra 
database is not publicly available. The reliability of sources and methods can be 
challenged, but overall with the research setting limitation these sources and 
methods were the most usable. Concerns for reliability raise the use of multiple 
sources, the limitation in which sources are documented, as well as the manual 
work required to build this database. 
                                                        
9 Database constructed with a joint work by Ville Airo, Heikki Arbelius, and Mikael Bruun. 
(2009). Espoo: Institute of Strategy, Helsinki University of Technology (currently Aalto 
University School of Science and Technology). 
10 The Wayback Machine. URL: www.archive.org  
11 AMADEUS database. URL: http://amadeus.bvdep.com  
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The survival rate was chosen as a measurement of industry’s overall 
competitiveness because of a few reasons. It as a measurement is actually able 
to capture the long term success of the industry as it calculates all the entries 
and exits. In addition, firm survival is one of the most used measurements of 
firm performance, which is indicated among others by Klepper (2002). This 
comment also addresses the construct validity of SUR. On the other hand, the 
survival rate was chosen partly because of the necessity, because other data of 
the performance was not available. For example, growth rates of any kind were 
not available, and any other meter that could be conducted from the company 
database with entries and exits was not seen as good as a meter as the survival 
rate. For example, an entry rate would be largely biased because many of the 
companies have origins long before the start of modern generic medicines 
industry. They are in a sense de alio or diversifying entrants. Also entries have 
diminished in the recent years and thus entry rate based meters would not 
describe the current situation that well. Also the density measurement in this 
kind of industry would not be easily divided into countries. It is a valid 
measurement at the European level, but when certain countries (like Finland) 
have only one entrant, density measurement at a country level was not seen 
justified. Based on this reasoning the highest construct validity can be reached 
with the chosen conceptualization. 
To conduct the survival rate for the companies in the country the following 
formula was used 
 
The highest score is 100%, which is obtained with at least one entry and not 
exits. The lowest score is 0%, which is obtained if exits are equal to entries. If 
there are no entries, this formula cannot be used. However zero entry basically 
means that there has not been a generic medicines industry and thus a country 
is fully out of the set SUR, which represents a successful industry.  
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This data is encoded in fuzzy sets using the indirect method. A case can be 
considered being fully in a set if the survival rate is 100%. This is because only 
then there is proof that industry has been competitive all the time. A case is fully 
out of the set if the survival rate is 20% or below or there has been no entries. In 
these cases majority of the companies have exited or there has not even been an 
industry. Therefore, qualitative coding uses the following six categories: 100% 
survival rate scores 1; 80% and above scores 0.8; 60% and above scores 0.6; 
40% and above scores 0.4; 20% and above scores 0.2; and below 20% as well as 
countries with no entries scores 0. For STATA analysis countries with no entries 
will be encoded in 0% survival rate. After that, in the above described way, the 
interval-scale survival data and qualitatively coded groupings are processed in 
STATA, which gives the predicted set membership scores that will be used in 
the analysis. 
5.3.2 Publicly Financed Health System (PHE) 
Second causal condition is the fuzzy set of countries with a publicly financed 
health system. It is abbreviated as PHE, because of the used data set of public 
health expenditure as a percentage of the total health expenditure. This causal 
condition reflects the effect public expenditure has on the performance of the 
industry. The use of this causal condition is based on two propositions. Public 
health expenditure experiences a lot of growth pressure (Proposition 10) and 
public policies are considered being in the key position for supporting generic 
medicines (Proposition 4).  
PHE is based on the data set of public health expenditure (the % of total health 
expenditure) in 2006 by World Bank. Data is available at the HNPStats – the 
World Bank’s comprehensive database of Health, Nutrition and Population 
(HNP) statistics12. All the cases have the data from 2006. HNP database was also 
chosen as the source for other statistical information, because it had the most 
                                                        
12 World Bank HNPStats Home. URL: http://go.worldbank.org/N2N84RDV00  
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comprehensive list of indicators and the reliability of data from World Bank is 
rather high. PHE, GNI, and O65 are constructed from the same database. 
Comprehensive data is publicly available at their website.  
Specifically, the data for PHE was chosen because it describes the share of the 
public expenditure in more detail than, for example, the coarser measurement 
of public health expenditure as a share of total GDP. Also there was no data 
available that would give even more detailed information about all the case 
countries. One of such data sets could have been the data for public expenditure 
as a share of total expenditure on prescription medicines. However, this data 
was available only for a few case countries and the decision was made to rather 
include more cases than get the more detailed data. Overall it can be argued that 
the construct validity of this chosen conceptualization was the highest.  
PHE is configured using the direct method in the spirit of Fiss (2008). The 
threshold for being completely out of the set is set to 61.6%. This is the average 
share of expenditure in the reference group of high income countries. Below the 
average there cannot be a high share of public health expenditure. A case is 
encoded to be fully in the set if the share is above 81.3%. This share is the share 
which Japan has and can be considered as an example of the country with a high 
share of public expenditure in health care. Also the share of 81.3% is close to the 
75th percentile of the case countries. 75th percentile is between the values of 
80% and 81.7%. The crossover point is set to about 76%, which is the 50th 
percentile of case countries.  
5.3.3 High National Income (GNI) 
Third causal condition is the fuzzy set of countries with high national income. It 
is abbreviated as GNI, because of the used data set of Gross National Income per 
capita. This causal condition reflects the effect level of the income has on the 
performance of the industry. The use of this condition is supported by the fact 
that wealthier countries use in general more on the health care and on 
pharmaceuticals, which can be seen from looking at the world medicine markets 
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(Proposition 8). Also economic growth has been in theory indicated as one of 
the reasons for the future success of the industry. This factor assesses if these 
are true for generic medicines.  
GNI fuzzy set is based on the data set of Gross National Income per capita in 
current US dollars measured using World Bank’s Atlas method from the same 
World Bank database as fuzzy set PHE. Data is from the year 2007 except in the 
case of the UK, which is from 2006. These were the latest available years. The 
construct validity of GNI does not raise many problems, but the internal validity 
of it possibly raises some. The use of GNI as a factor is maybe the least 
supported by the theory. 
GNI is configured using the direct method similarly as in the PHE case. Here the 
case is considered being completely out of the set if the GNI per capita is below 
$ 11,906. This is the threshold World Bank uses for high income countries. A 
case is considered being fully in the set if the GNI per capita exceeds $ 46,040, 
which was the GNI per capita in the United States in 2007. This value is close to 
the 75th percentile of the case countries. The crossover point is set to $ 37,572, 
which was the average GNI per capita for high income countries in 2007.  
5.3.4 High Share of Elderly People (O65)  
Fourth causal condition is the fuzzy set of countries with a high share of elderly 
people. It is abbreviated as O65, because of the used data set of the share of the 
population aged 65 years and over. This causal condition reflects the effect 
elderly people have on the performance of the industry (Proposition 11). 
Statistics and theory indicate that from the age of 65 onwards the health care 
expenditure of a citizen dramatically increases. To capture this change in 
expenditure and see its effect on the overall success of the industry, the use of 
this data is justified.  
O65 is based on the data set Population ages 65 and above as a share of total 
population in 2007 by World Bank. Data comes from the same database as PHE 
and GNI and all the countries have the 2007 data, which is the latest available. 
5 Data and Analysis 89 
The conceptualization of O65 raises close to none validity and reliability issues. 
The use of O65 as well as its conceptualization is well supported by the theory. 
O65 is configured using the direct method similarly as in the cases of PHE and 
GNI. The case is considered being fully in the set if the share of elderly people 
exceeds 17.7%, which was the average value in the euro area in 2007. This value 
sets in the case countries to about 90th percentile. The case is considered being 
fully out of the set if it falls below 12.3%. This is the value the United States has 
and it is really low for industrialized countries. The crossover point is set to 
14.9%, which was the average of the high income countries in the world in 
2007.  
5.3.5 Coordinated Market Economy (COO)  
Fifth causal condition is the fuzzy set of countries with coordinated market 
economy. It is abbreviated as COO, because of the used data set of Coordination 
index (Hall & Gingerich, 2004). This causal condition reflects the effect level of 
the coordination in the national economy level has the performance of the 
industry.  
COO was chosen as causal condition, because according to Varieties of 
Capitalism theory it should indicate something about the performance of the 
industry in a given country (Proposition 1). According to theory the level of 
coordination, from liberal to fully coordinated, affects the performance of 
industries in that country. Both of them have certain industries that they 
support more than the others. In the most simplistic view, this is based on the 
idea that liberal system supports radical innovation and coordinated system is 
for incremental innovation. For this analysis it is understood that according to 
theory generic medicines should perform better in coordinated environment 
regardless of the fact that innovative medicines are one of the primary examples 
of the industries that perform better in liberal environments (Proposition 2).  
Another measurement of the economic systems performance in the Varieties of 
Capitalism theory is coherence, which was discussed in the literature review 
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chapter. This was thought as possible causal condition, but it was seen that 
actually coherence of a system affect more on the higher level national economy 
issues. Theory says that coherent economies outperform the incoherent ones. 
This says only a little about the specific industries and therefore implications for 
generic medicines industry are far harder to get from the coherence index than 
from coordination (Proposition 3). 
Majority of the COO scores come from Coordination index by Hall and Gingerich 
(2004) from 1990-1995. They have calculated the scores for each of the OECD 
nations, which they had data, based on factor analysis. They give coordination 
scores for these countries in the closed interval from 0 to 1, where 1 is totally 
coordinated and 0 is totally uncoordinated or liberal. Countries are set at this 
interval indicating the level of the coordination they have in their economic 
system.  
The fuzzy set calibration of the COO was done using the indirect method, but 
with certain modifications. First countries that are presented in the 
Coordination index were transformed to six fuzzy set classes. In this division 1 
is for coordinated market economy with Germany and Austria with full scores. 0 
is for uncoordinated or liberal market economy, where the UK scores only 0 in 
Europe. Other scores were linearly transformed. At this point, the indirect 
method is terminated and these scores will be used as the fuzzy set scores. 
Termination was done because there was not enough statistical data to 
construct the final scores. However, these types of scores without any transfer 
procedure have been used previously in fsQCA studies (e.g. Katz et al., 2005). 
Therefore, this is not seen as a problem or a major limitation.  
Hall and Gingerich analysis excludes nine case countries: Czech Republic, 
Greece, Hungary, Iceland, Poland, Slovak Republic, Lithuania, Slovenia, and 
Romania. Of the unanalyzed countries, Central and Eastern European (CEE) 
countries are set to 0.6 based on the idea that is presented by Lane (2005) that 
indicates these countries having relatively high state coordination. CEE 
countries are said to represent continental European models in many ways. So 
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they are seen to be closer to coordinated market economy than liberal and they 
are also not in the ambiguous position. 0.8 is seen as too big score for these 
countries’ coordination index. Moreover, Iceland is set to 0.8 to correspond with 
the majority of the Nordic countries. Furthermore, Greece is set to 0.8 based on 
the analysis by Knell & Srholec (2005). Their analysis indicates Greece to have 
the highest level of coordination of all European countries. When comparing 
this with the original theory and Germany and Austria, which score relatively 
low on coordination in Knell and Srholec analysis, it is understood that this 
analysis has different underlying assumptions. Therefore, the full score of 1 to 
Greece is discarded, but it is understood that Greece has a high level of 
coordination and thus has the score of 0.8. In conclusion, the main reliability 
issue in the use of COO is that the data possesses sources for random error that 
emerge from the use of multiple sources. On the other hand, the 
conceptualization of COO is in line with the theory.  
5.3.6 Established Generic Medicines Promotion System (RPS) 
Sixth and final causal condition is the fuzzy set of the countries with an 
established generic medicines promotion system. It is abbreviated as RPS, 
because of the used data of having reference price systems in place. This causal 
condition reflects the effect promotion of the generic medicines has on the 
performance of the industry. Mrazek and Frank (Mossialos et al., 2004, p. 247) 
argue that in general countries that have greater generic medicines penetration 
into their markets have implemented policies that favor their use. 
Reference price system specifically was chosen as a causal condition, because in 
theory patent legislation is enabler for the generic medicines industry 
(Proposition 6), but the promotion legislation decides its success in a given 
country. According to the analysis, reference price system is one of the most 
important parts of the generic medicines promotion (Proposition 7). Other parts 
of the promotion include generic prescribing and substitution. From these 
different types of promotions reference price system was chosen because is 
seen to have the most effect on the level of promotion. This is because of three 
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reasons. Firstly, it cannot be overturned by any indication of the prescribing 
physician. Secondly, it has only two states of being available or not being 
available, in comparison to prescribing or substitution, which can be indicative 
or obligatory when they are available. Thirdly, it has the most direct effect on 
the economy of the health care. It was also researched whether these three 
forms of promotion could be combined with a function. However, it was seen 
that combination of these would make the scoring extremely complex and 
therefore the idea was discarded.  
RPS is based on the data whether the reference price system is in place or not. 
Data is mainly from Pharmaceutical Pricing and Reimbursement Information 
(PPRI) (Vogler et al., 2009; Vogler et al., 2008). However, this data is available 
from many sources. Data is from the year 2007, because that is the year 
majority of the other data is also from. Therefore Finland has not yet 
implemented the reference price system, which was enforced in 2009. RPS is 
calibrated to fuzzy set as a crisp set, where 1 is if the reference price system is in 
place and 0 is if not. Reliability of the data source is high as it can be verified 
from multiple other sources. Validity, especially construct validity, issues in RPS 
is raised by the fact that other areas of promotion legislation are not included in 
it. However, as discussed it is seen that the combination of all the areas of the 
promotion might have been an even bigger source of validity problems.  
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6 Findings 
After procedures described in Chapter 5, fuzzy sets are obtained. The fuzzy sets 
are presented in Table 8. The full data table and the qualitative codings for the 
applicable fuzzy sets are presented in Appendix 4. Finally before the analysis all 
the values below the full membership score of 1 in these fuzzy sets were added 
a constant of 0.001 following the proposition by Fiss (2008). This can be 
observed from the table and was discussed in Chapter 4.4 Software.  
Table 8: Fuzzy Set Scores 
Case PEN SUR PHE GNI O65 COO RPS 
AT 0.457 0.001 0.471 0.831 0.871 1 0.001 
BE 0.087 0.202 0.311 0.781 0.941 0.801 1 
CH 0.130 0.307 0.031 1 0.761 0.601 1 
CZ 0.977 0.975 1 0.061 0.411 0.601 1 
DE 0.939 0.817 0.561 0.621 0.991 1 1 
DK 0.544 0.202 1 1 0.681 0.801 1 
ES 0.010 0.618 0.261 0.281 0.901 0.601 1 
FI 0.530 0.975 0.471 0.921 0.821 0.801 0.001 
FR 0.063 0.975 0.881 0.611 0.821 0.601 1 
GR 0.201 0.975 0.051 0.201 0.981 0.801 1 
HU 0.986 0.602 0.241 0.051 0.661 0.601 1 
IE 0.023 0.307 0.751 0.971 0.011 0.201 0.001 
IS 0.377 0.975 0.971 1 0.031 0.801 1 
IT 0.534 0.899 0.611 0.381 1 0.801 1 
LT 1 0.001 0.211 0.041 0.701 0.601 1 
NL 0.481 0.389 0.901 0.951 0.411 0.601 1 
NO 0.240 0.001 0.991 1 0.471 0.801 0.001 
PL 1 0.602 0.211 0.041 0.141 0.601 1 
PT 0.396 0.917 0.231 0.101 0.911 0.801 1 
RO 0.895 0.260 0.561 0.031 0.501 0.601 1 
SE 0.266 0.975 0.961 0.971 0.951 0.601 0.001 
SI 0.973 0.260 0.301 0.131 0.761 0.601 1 
SK 1 0.001 0.231 0.051 0.031 0.601 1 
UK 0.911 0.389 1 0.751 0.801 0.001 0.001 
Fuzzy set values should differ across cases. Differences between cases apply 
here as can be observed from the table. Different conditions across countries 
were evident after the industry analysis, but also the differing sets are required 
to obtain any interesting and usable results at all from the fuzzy set analysis. 
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This is important also for the internal validity. Internal validity also requires 
that overall relationships between the factors are non-trivial. Based on the 
theoretical and empirical analysis presented previously in the thesis as well as 
building the fsQCA setting the internal validity of the factors is reached.  
After pointing out the necessary variation between cases the fs/QCA software 
was used to obtain results. Based on the normal procedure for studies with a 
small number of cases (Ragin, 2008c) frequency cutoff was set to 1. If frequency 
cutoff were set any higher, the selected cases would have captured less than 
50% of the cases, which would have been significantly lower than the indicated 
minimum level of 75-80%. Similarly the consistency cutoff is set to 0.85, which 
is in line with the theory. Preliminary analysis did not indicate a reason for 
setting consistency cutoff value any lower. Neither was there enough evidence 
to set it any higher.  
To present the results in more readable format Ragin and Fiss (2008) have 
recently introduced a notation to illustrate results. In this notation, there are full 
circles, which indicate the presence of a condition, and crossed circles, which 
indicate the absence of a condition from the obtained causal combination. In 
addition to that, large circles indicate core conditions that are part of the both 
parsimonious and complex solutions, while small circles indicate peripheral 
conditions that are present only in complex solutions.  
Table 9 shows the results for fsQCA of successful generic medicines markets. 
Solutions are divided into numbers based on the parsimonious solution they 
represent. In other words, there are total of four obtained parsimonious 
solutions. All the complex solutions that have the same parsimonious solutions 
included in the configuration are categorized under the same number. In those 
cases, letters after a solution number indicate differences in the complex 
solutions. The descriptive statistics are obtained from the complex solution. 
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Table 9: Configurations for Achieving Successful Generics Markets 
 
Results show relatively high consistency throughout. All four solutions are 
within the limits of acceptable consistency, which is above 0.80. They actually 
have even higher consistency than 0.85, which was the limit for individual lines 
at the truth table. In addition, similar consistency in all the solutions indicates 
that these different configurations similarly lead to the same result of successful 
generics markets. In other words, there are possibly at least four distinctive 
paths to successful generic medicines markets in Europe.  
Solutions 1a and 1b indicate similar paths to successful markets. In this solution, 
the country has for the core conditions a relatively low share of elderly people 
and low income levels. For the peripheral conditions coordination in the 
economy is similarly high as well as countries have established systems for 
1a 1b 2 3 4
Competitive domestic generic medicines industry
Publicly financed health system
High national income
High share of elderly people
Coordinated market economy
Established generic medicines promotion system
Consistency 0.95 0.92 0.94 1.00 0.88
Raw Coverage 0.22 0.18 0.08 0.07 0.11
Unique Coverage 0.08 0.04 0.07 0.06 0.06
Overall Solution Consistency
Overall Solution Coverage
Notes :
Solution
0.94
0.47
Precense of the condition in the complex and parsimonious solutions
Absence of the condition from the complex and parsimonious solutions
Absence of the condition from the complex solution
Precense of the condition in the complex solution
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promoting generic medicines. Financing in the health care and domestic 
industry’s competitiveness differ for these solutions. The core conditions in the 
solutions 1a and 1b refer clearly to Eastern European countries. Therefore, 
partial empirical evidence can be found in number of Eastern countries. Many 
countries are close to at least some of the conditions. Especially, Poland and 
Slovak Republic offer close empirical evidence for the solution 1a and Czech 
Republic for the solution 1b. In addition, Poland has some empirical evidence 
for the solution 1b. For 1b the evidence from Poland differs to some extent from 
the solution because the domestic industry has not been very competitive.  
Solution 2 offers the second path to successful markets. In core conditions, 
solution 2 shows that having low public financing in health care combined with 
not having promotion to generics will lead to successful markets. This solution 
has only little empirical evidence. Two countries that are the closest in these 
aspects are Austria and Finland. However, the factor about the low public health 
care financing is not that evident in these countries. The share of public 
financing is about average in Europe. However, the peripheral conditions fit 
these countries. In addition, these countries do not have very successful markets 
either. Furthermore, in 2009 Finland adapted the RPS, which indicates that this 
combination was at least not that viable in reality.  
Solution 3 indicates the third path to successful generics markets. Here the core 
conditions indicate the absence of competitive domestic industry, a high share 
of elderly people and the absence of the promotion systems. For the peripheral 
conditions this solution indicates publicly financed health systems, high national 
income and the absence of state coordination in the market economy. For the 
solution 3, the UK provides empirical evidence. Another liberal market economy 
in Europe, Ireland, differs from this solution by having a low share of elderly 
people and interestingly also having unsuccessful generics markets.  
Solution 4 has for the core conditions poorly competitive domestic industry, a 
low share of elderly people, and established promotions systems. In addition, 
peripheral conditions indicate publicly financed health care systems, high 
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income levels, and coordination in the market economy. For the solution 4, the 
Netherlands offers empirical evidence.  
The coverage of the solutions remains relatively low: all raw coverage scores 
stay under 0.25. This can be seen also from the partial lack of empirical 
evidence. However, this does not raise much concern as in many cases high 
consistency has a tendency to indicate low coverage. Furthermore, consistency 
is more important from two figures and therefore results can be accepted.  
The overall coverage of the solution is higher than the coverage of the specific 
solutions. Overall coverage is about 47%. This indicates that almost half of the 
configurations that lead to the successful generic medicines markets are present 
within these solutions. On the other hand, there are still a number of 
configurations leading to the successful markets that are not presented in these 
solutions. These solutions do not meet the imposed consistency and frequency 
thresholds and are therefore excluded.  
Moreover, there is not one condition that is present in all of the solutions. This is 
even though, for example, at the level of coordination there are only two 
countries that can be categorized as liberal. Solution 3 provides a configuration 
for achieving successful markets in liberal market economies. The absence of 
such condition that is present in all the solutions possibly indicates that no 
necessary conditions can be found for achieving successful generic medicines 
markets. For the hypotheses presented in setting the fuzzy sets, this means that 
there can be an environment, where some of the hypotheses might not be 
applicable. For example, it is doubtful if the industry’s performance is enhanced 
in the liberal market economies, by increasing the coordination. It was neither 
intended nor possible with the chosen methodology to analyze the separate 
effect of the causal conditions on the industry’s performance.  
Furthermore, clearly all of the solutions have at least some conditions absent in 
their configuration. According to theories and the hypotheses of conditions, the 
best market conditions should be achieved with all the conditions being present 
in the configuration. Currently a country with all the conditions present is not 
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reality and a possibility to analyze the real effect of having all conditions present 
is limited. However, from the obtained solutions it can be seen that each absent 
condition can be fought back with a configuration of others. This shows that 
actually all the conditions do not need to be present to achieve successful 
generic medicines markets.  
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7 Discussion and Conclusions 
7.1 Conditions for Successful Generic Medicines Markets 
Analyzing the industry as complex as generic medicines called for new types of 
methods. A partly iterative process of studying the industry with the proposed 
frameworks from Varieties of Capitalism and fsQCA proved to be successful in 
this context by producing concrete findings. Eventually each part of the analysis 
complemented every other and the study was capable of providing reasonable 
and interesting results and implications. In that respect, the study confirmed 
current views, brought new ideas to the field, as well as opened new research 
avenues. However, there is still work in building the validity of the methods 
further and in bringing these results to practice.  
The understanding about the industry dynamics suggests that there cannot be 
simple and straightforward answers to research questions, which is also usually 
the case with this kind of research setting. For the first sub-problem, based on 
the previous discussions in the thesis it is clear that the patent and intellectual 
property rights legislation is something that is needed for the industry to exist, 
but it does not decide the success of the industry. The success is largely decided 
by the promotion legislation. The question about how regulation influences the 
overall dynamics has a more complex answer. Regulation is only one part of the 
affecting factors and its effect depends on the other factors as well as the inner 
relations of all the factors. For example, other conditions affect the role 
regulation has in setting industry dynamics in certain environments. Other 
central factors that were identified from the propositions provide a partial 
answer to the sub-question two about the other affecting conditions. Together 
with these conditions regulation and coordination influence the industry 
dynamics. Therefore, in this complex environment the main research question 
about the favorable conditions does not have an answer that finds the one single 
most suitable set of conditions for generic medicines industry in Europe. 
However, it can be argued that there are conditions that promote success more 
in certain regions than others. These were illustrated in Chapter 6.  
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To deepen the understanding about the favorable business environments the 
analysis of industry dynamics and fsQCA suggests that European countries can 
be categorized into five groups. The basis for division comes from the 
previously found configurations for successful markets. However, since 
currently in all regions there possibly cannot be found a successful 
configuration, division is also done based the overall characteristics of the 
countries as identified already for the purposes of fsQCA. Five groups that are 
found are: Eastern European countries, Liberal market economies, Nordic 
countries, Mediterranean countries, and Central European countries. These 
groups are presented in Table 10.  
Table 10: Categories of the European Generic Medicines Markets 
 
Eastern 
European 
countries 
Liberal 
market 
economies 
Nordic 
countries 
Mediterranean 
countries 
Central 
European 
countries 
Characteristic Low income  
Low share of 
elderly  
Coordinated  
Established 
promotion 
Liberal  
High 
income  
Public health 
care 
High income 
Similar 
coordination 
("Nordic") 
Relatively low 
penetration  
Successful domestic 
companies 
Low generics 
penetration 
High share of elderly 
Similar coordination 
("Mediterranean") 
Established 
promotion 
Non-public health 
care 
High income 
Corresponds 
fsQCA 
solution no. 
1 3 - - 4 (partly) 
Example 
countries 
Czech 
Republic 
Hungary 
Lithuania 
Poland 
Romania 
Slovak 
Republic 
Slovenia 
Ireland 
The UK 
Denmark 
Finland 
Iceland 
Norway 
Sweden 
France 
Greece 
Italy 
Portugal 
Spain 
Austria 
Belgium 
Germany 
The 
Netherlands 
Switzerland 
Problems Overall low 
health 
expenditure  
Non-
successful 
generic 
medicines 
companies 
Varying 
promotion 
and success 
of companies 
Poor performance 
(medicines) despite 
the supporting 
aspects 
Copied medicines  
Varying 
policies and 
overall 
success of the 
generics 
In the table, first the characteristics of the group are presented. These are the 
main differentiating factors between the regions. In addition, the corresponding 
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solution number from fsQCA is presented for those regions where successful 
configurations are found. In the “example countries” -line all the case countries 
are divided into the region they fit the best. Finally, key problems for each 
region are presented. Problems can be related to market conditions, to 
companies, or to public policy.  
The solution number from fsQCA that corresponds to some countries of the 
region offers a clear answer to the most suitable conditions in that region. The 
regions that currently do not possess the combinations of conditions leading to 
successful markets can also develop such conditions but has not yet done so. In 
these regions, a model for successful markets can come from other regions or 
from a successful country. However, maybe the most important thing for all the 
regions to achieve successful markets is to achieve the unification of the 
promotion legislation. The effect of promotion legislation on market conditions 
is maybe the biggest from all the identified factors and if it is not unified it 
lowers the efficiency of total markets.  
In comparison to previously presented studies, the findings of the study are in 
most aspects similar. First of all, Varieties of Capitalism (VoC) argues that 
coordination in market economy should be more suitable for generic medicines. 
This is because generic medicines are closer to industries needing incremental 
innovation than radical innovation. From the complex solutions in fsQCA (Table 
9) four out of five support this idea and have coordinated market economy 
present in the configuration. As innovation is one of the main ideas in VoC, 
solution 4 is a little bit disturbing as it shows some contradiction of having 
coordinated market economy with the absence of competitive domestic 
industry. In coordinated economies, industry should also be competitive. Then 
again, for competitive domestic industry and coordination other solutions are 
more or less in line with the previous studies.  
Moreover, in comparison to fsQCA studies in general these findings seem to be 
in line. The reasoning from the theory and previous studies for choosing six 
causal conditions appears to have been relatively successful. Results give 
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solutions that are able to explain the complexities in the business environment. 
The solutions are not too complex. Also there is no reason to regard these 
results as totally random. What is more, combining VoC with the set theoretical 
analysis methods, as has been suggested, seems to have been working relatively 
well. The micro- and meso-level analysis gives usable results for generic 
medicines industry, but also contributes to the macro-level. 
7.2 Implications to the Theory of Capitalist Variety 
Theoretical implications in the study also relate to Varieties of Capitalism (VoC) 
and fsQCA. In neither of the fields nothing groundbreaking was achieved, but 
some of the presented critique in these fields could be addressed. Especially in 
VoC the study is able to validate the proposed future orientation of the studies 
by conducting a study well in that spirit. Based on the study it can be said that 
fsQCA in this kind of context is definitely a possible way ahead for the analysis 
in VoC.  
Another clear implication for fsQCA is seen from the analysis setting. As was 
presented, the study used multiple data sets with multiple calibration methods. 
In general studies utilizing fuzzy sets when studying comparative advantages 
between nations have used one dataset or otherwise comparable data. Previous 
studies have also used similar calibration methods for all of the factors. (E.g. 
Pajunen, 2008; Schneider, Schulze-Bentrop, & Paunescu, 2009.) After getting 
realistic results with the chosen method in the study, a conclusion is that it is 
possible to use a variety of sources and calibration methods in these kinds of 
studies regardless of the current practices. Based on the study it could even be 
concluded that in the spirit of proposed VoC future orientation the use of 
multiple datasets is encouraged. The setting in the study does not influence the 
results significantly, but deepens the analysis substantially. The study provides 
an argument for using multiple datasets even though this has not been a 
practice in the recent fsQCA studies. 
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The above presented categorization of the European generic medicines markets 
(Table 10) offer empirical evidence to support VoC theory. The grouping 
resembles some of the labels presented under VoC earlier. The resemblance 
itself is quite remarkable and gives support to the VoC theory. In general the 
idea that European countries can be classified to seemingly homogeneous 
groups supports the labeling approach in VoC. The labeling approach has been 
experiencing a lot of critique, but these results argue against those. However, 
these results are likely to only be applicable in specific context as the analysis 
has focused on generic medicines. Nevertheless, as moving to micro-level 
analysis has been the pointed direction for VoC studies, overall these results 
support the original theory as well as the future orientation of VoC. In other 
words, it seems that the pointed direction is right and under these assumptions 
the presented VoC theories are valid.  
Furthermore, in the VoC field there have been two groups: one arguing 
convergence and one arguing against it. Currently maybe more support is on the 
side of not converging market economies, but the convergence ideas are not 
totally gone. In the study, the possibility to label countries to distinct groups 
argues clearly against the convergence of CMEs to LMEs, or against any 
convergence to one type of market economy. So the study takes a similar route 
than the majority of scholars in VoC and offers micro-level evidence against the 
convergence. Notable at this and at the above labeling idea is that underlying 
assumptions for the analysis partly come from the original theory, which 
supports labeling. In this sense, these arguments can be biased. However, 
because labeling is only reinforced by the other factors in this analysis, the 
presented arguments supporting the labeling approach can be considered valid. 
If there were convergence and the labeling approach was groundless, other 
factors in the analysis would make the categorization much harder than what is 
presented in Table 10 above.  
104 Ville Airo 
7.3 Managerial Implications 
For companies operating in the generic medicines industry the future looks 
interesting. As has been brought up, there are a lot of changes in the horizon 
that affect the industry and its dynamics: patent expiries, the blurring of the 
industry borders with innovative medicines giants that are emerging to the 
generic medicines markets as well as the emergence of biosimilars, and the 
changing demography to name a few. Many of these points have already been 
analyzed here and in different other contexts. Therefore those are relatively 
well known for the companies. The implications that rise from the study 
therefore do not focus on these, but instead try to present maybe more general 
implications that affect the whole industry.  
The first clear implication comes from the analysis of industry population: it 
seems that there is only a little room for new companies. Especially difficult this 
environment seems for small companies. Currently, it seems that bigger 
companies are the market winners. The industry is characterized by the 
mergers and acquisitions (M&A) activity where bigger companies acquire the 
smaller ones. Companies, at all levels of the generic medicines industry, need to 
be ready for escalating M&A activity. One big reason for M&A activity seems to 
be the idea of capturing scale advantages. However, on the basis of the study 
even more important seems to be the market access to different regions and, 
furthermore the ability to obtain capabilities from these different regions. The 
best performing companies in the industry are widely diversified global giants.  
Looking at Table 10 above some more detailed implications for companies can 
be seen. First of all, five categories of diversified markets imply that companies 
need to tailor their strategies for each of these regions where they are active if 
they want to be competitive in these regions. Policies as well as the market 
characteristics differ between the regions and this definitely has an effect on the 
companies operating in these regions. For example, a country group called 
Liberal market economies has a good basis for having markets for generic 
medicines and there is also evidence for this. In Ireland, there is also potential 
7 Discussion and Conclusions 105 
for substantial growth in the market value. However, noticeable for the 
companies operating in this environment is that the domestic companies have 
not been that competitive. This clearly needs to be assessed in the strategies.  
In the Eastern Europe growth potential from getting more penetration is small, 
but the rise in income levels might cause the prices go up and therefore there 
might be market potential. In Nordic countries, the varying promotion and the 
varying success of the domestic companies provide challenges. Varying 
promotion legislation might be a reason for some countries having successful 
domestic companies. This is because market sizes are relatively small and the 
challenge of understanding legislation might work as an entry barrier.  
In Mediterranean countries, the biggest problem still seems to be the copied 
medicines. The basic requirements for markets seem to be in order, but still 
markets are small. There are really high shares of elderly people as well as 
established promotion systems in the Mediterranean countries. The only thing 
that is missing is the substantial public financing in health care, which could also 
be a source for not having high penetration rates.  
In Central European countries policies and other market characteristics are 
different from country to country. Germany offers successful markets with all 
the identified factors supporting the markets. On the other hand, there are also 
countries like Belgium where penetration rates are very low as well as the 
survival of domestic industry is bad. It seems that for Central Europe there 
needs to be the most individualized strategies for each country.  
7.4 Public Policy Implications 
Similarly, as for companies in generic medicines industry, the future is 
interesting for public policy makers. As presented, the rising health care costs 
need to be contained. However, the full support for generic medicines is not 
possible, because the innovative medicines industry is also needed to find new 
molecules. For public policy the implications from the study are in consequence 
focused on making the markets more effective overall.  
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As has been argued, the inner markets of generic medicines in Europe are not 
reality. The biggest problem preventing similar markets is the differences in 
promotion legislation. Every country has its own policies, which make the 
market heterogeneous. The first implication from this would be that EU would 
set the promotion legislation like they now do with the patent legislation. This 
should in theory greatly increase the overall effectiveness of the markets. Still 
since this requires big institutional changes, in the current EU this kind of 
arrangement does not seem possible. Therefore, to take the first step towards 
pan-European policies, countries within certain regions should together 
formulate similar policies. This would be in line with the proposition of 
companies forming strategies for regions above presented regions. Having more 
transparency in policy setting allows companies to formulate their strategies 
better, which increases competition. In market economies, this should have the 
effect of making the overall markets more effective.  
When setting the public policies within regions, the results of the study could be 
utilized. As the categories presented earlier in Table 10 are a result of in-depth 
analysis of the industry, there are similarities already between the countries 
within each category. These could be utilized as the starting point of unified 
public policy setting. For example, in Mediterranean countries the increases in 
public health care support could be decided together. The setting of policies 
within regions is supported by the fact that only four distinct ways to achieve 
successful generic medicines markets have been identified as was presented in 
Chapter 6 Findings.  
In public policy setting the fact that some factors do not change instantaneously 
needs to be taken into account. Especially the income levels of the country and 
the share of elderly people cannot be changed radically but their change is 
inevitable. This means, for example, to Eastern European countries that the 
markets that are now functioning need to change together with the changing 
demographics and income levels. If Eastern European countries catch Western 
European countries in these aspects, it could well be that the best market 
conditions for these markets are closer to successful market conditions in 
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today’s Western Europe than today’s Eastern Europe. As policy changes are 
neither fast, these aspects need to be taken into account already. The 
homogenization of European generic medicines markets can partly happen 
because of the inevitable convergence towards the same economic levels in the 
EU.  
7.5 Limitations and Directions for Future Research 
The main limitations of the study are associated with data. The study combined 
a few datasets and used different calibration methods to those and tried to 
capture more aspects of the industry that way. Depending on the point of view 
this either could be a strength or weakness in the study. The method proved to 
be successful here, but also this might have reduced the validity. Practical 
problems when taking the study towards micro-level analysis inhibit possibility 
to follow closer the current practices in the field. At micro-level, it is almost 
impossible to get the data from a single source.  
Also the data for single fuzzy sets, for PEN and COO especially, can be argued not 
to be coherent. In those cases data for a single fuzzy set comes from a few 
sources and at some level those sources are not comparable. For the generic 
penetration, the problem might not be that big since overall the numbers are 
similar across different data set. However, especially Greece having a very high 
coordination in the economic system can be misinterpreted. In this case the 
definitions of coordinated and liberal systems can be quite different between 
two used sources. Furthermore, the majority of COO data from Hall and 
Gingerich (2004) is rather old and has also experienced an indirect critique. The 
same critique that addresses the whole VoC theory addresses the coordination 
index created from it.  
Another source of errors in the study is the whole research setting. Even though 
the theories as well as the industry have been studied intensively and 
profoundly, in complex environments there are some aspects that could have 
been missed. When combining this to the novel analysis method, which is 
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largely dependent on the researcher’s conceptualization of the problem, it can 
raise questions about the repeatability of the study. It can be argued that this 
kind of study can be done in multiple ways. In other studies there could be other 
factors and therefore results could differ. These limitations offer fruitful 
avenues for the future research in all three areas discussed. The chosen 
approach and the level of the analysis mainly determine which limitation causes 
most problems and then which part of the data needs to be re-examined.  
The proposals for meso-level present maybe the clearest continuum for the 
study. In this path, the theoretical contribution to all the theoretical fields of the 
study could be deepened the most. Especially this is true for fsQCA, where in the 
study the analysis has been only at one level. In other words, secondary factors 
affecting the chosen factors have not been studied. To deepen this analysis, the 
second level factors could be analyzed more. Analysis could be conducted in 
multiple ways and methods but if wanting to remain in fsQCA setting Goertz and 
Mahoney (2005) present the idea of analyzing at multiple levels with fuzzy sets. 
This analysis incorporates even more of the inner relations between factors. 
Moreover, this setting could include more factors affecting the industry. For 
example, examination of how the legislation for promotion evolves could be 
fruitful. In deepening this analysis all the other legislation for promotion as well 
as the incentives for professionals, and the media campaigns for patients and 
professionals could be evaluated more. These could be incorporated together to 
form a new factor to replace RPS factor in the study. Acquiring considerable 
amount of new data as well as unifying current data will be required in this 
path.  
The study could also be moved in the direction of macro-analysis. In the study, 
the capitalist variety has been used as a source of comparative advantage. It 
could be interesting to analyze also in other direction and see the effect generic 
medicines industry and all the other factors have on the coordination changes. 
In this analysis more understanding needs to be built on the institutional 
environment. The understanding about the policy setting procedures as well as 
other national and international systems needs to be strengthened. In particular 
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the limitations in the coordination data need to be dealt in this approach. This 
approach should contribute most to the Varieties of Capitalism. 
At a micro-level, the success of the companies could be analyzed more. Even if 
not doing this in the fsQCA setting, the analysis of other factors in company 
performance could provide even more practical implications for companies in 
generic medicines industry. For fsQCA, as was discussed briefly in the 
explanation of the SUR factor, company success could be further analyzed by 
obtaining various other indicators about their performance. In addition, 
controlling the performance indicators with descriptive factors, like structure, 
operational environment, and strategy, could provide more practical 
implications for companies. Also one possible way of analyzing performance 
could be the analysis of the factors leading to poor performance. At micro-level 
it is also vital to understand that the changes are the most rapid. This presents 
constant challenges for managers and they thus need constant updates on the 
status of the industry. 
At all levels, the turmoil in the world economy affects the results somewhat. The 
study is largely based on the data before credit crisis. In the data, the growth in 
the generic medicines industry was argued to continue without disruption to 
the future. However, it seems that the decline in the growth rates is almost 
certain also in the pharmaceutical industry (Gorka, 2009). However, maybe the 
constant need for health care makes this decline smaller than in some other 
industries. Nonetheless, this effect should be analyzed more to adjust the 
proposed implications to match the current situation. 
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Appendices 
Appendix 1: Exchange Rates 
 US dollars British pounds Japan yens 
One euro equals 1.50 0.90 133 
Source: Kauppalehti 23.11.2009 
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Appendix 2: Summary of the Generics Promotion in European 
Countries 
Country 
Generic 
Prescribing a 
Generic 
Substitution a 
Reference Price 
System b  
Austria Not allowed Not allowed No 
Belgium Indicative INN 
prescribing 
Not allowed Yes, since 2001 
Bulgaria N.a. Not allowed Yes 
Cyprus Not allowed in the 
private sector (only 
in the public 
sector) 
Not allowed in the 
private sector 
(obligatory in the 
public sector) 
No 
Czech Republic Indicative INN 
prescribing 
Indicative generic 
substitution 
Yes, since 1995 
Denmark Not allowed Obligatory generic 
substitution (also 
for non-
reimbursable 
pharmaceuticals) 
Yes, since 1993 
Estonia Obligatory INN 
prescription 
Indicative generic 
substitution 
Yes, since 2003 
Finland Indicative INN 
prescribing 
Obligatory generic 
substitution 
Yes, since 2009c 
France Indicative INN 
prescribing 
Indicative generic 
substitution 
Yes, since 2003 
Germany Indicative INN 
prescribing 
Obligatory generic 
substitution 
Yes, since 1989 
Greece Not allowed Not allowed Yes, since 2006 
Hungary Indicative INN 
prescribing 
Indicative generic 
substitution 
Yes, since 1991 
Iceland Allowed Not allowed Yes, since 1995 
Ireland Indicative generic 
prescribing (INN or 
brand name) 
Not allowed No 
Italy Indicative INN 
prescribing (INN, 
brand name and 
generic name) 
Indicative generic 
substitution 
Yes, since 2001 
Latvia Indicative INN 
prescribing 
Obligatory generic 
substitution 
Yes, since 2005 
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Country 
Generic 
Prescribing a 
Generic 
Substitution a 
Reference Price 
System b  
Lithuania Obligatory generic 
prescribing 
(writing of brand 
name only with 
justified reason) 
Indicative generic 
substitution 
Yes, since 2003 
Luxembourg N.a. Not allowed No 
Malta N.a. Indicative generic 
substitution 
No 
Netherlands Indicative INN 
prescribing 
Indicative generic 
substitution 
Yes, since 1991 
Norway Indicative generic 
prescribing 
Indicative generic 
substitution 
No 
Poland Indicative generic 
prescribing (INN, 
brand name or 
generic name) 
Indicative generic 
substitution 
Yes, since 1998 
Portugal Obligatory INN 
prescribing 
Indicative generic 
substitution 
Yes, since 2003 
Romania Allowed Allowed Yes 
Slovak Republic Indicative INN 
prescribing 
Obligatory generic 
substitution 
Yes, since 1995 
Slovenia Indicative INN 
prescribing 
Indicative generic 
substitution 
Yes, since 2003 
Spain Indicative INN 
prescribing 
Allowed Yes, since 2000 
Sweden Not allowed Obligatory generic 
substitution 
N (existed from 
1993 to 2002) 
Switzerland Not allowed Allowed Yes, updated 2002 
(works slightly 
differently) 
United Kingdom Indicative generic 
prescribing 
Not allowed No 
Notes: 
a
 = PPRI Report (Vogler et al., 2008) 
b
 = New PPRI analysis including Spain (Vogler et al., 2009) 
c
 = Esitteitä 2009:3 (Finnish Ministry of Social Affairs and Health, 2009) 
N.a. = Information not available 
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Appendix 3: Basic Data on the Case Countries 
Case No. Abbreviation Country EU Accession 
1 AT Austria 1995 
2 BE Belgium 1957 
3 CH Switzerland N/A 
4 CZ Czech Republic 2004 
5 DE Germany 1957 
6 DK Denmark 1973 
7 ES Spain 1986 
8 FI Finland 1995 
9 FR France 1957 
10 GR Greece 1981 
11 HU Hungary 2004 
12 IE Ireland 1973 
13 IS Iceland N/A 
14 IT Italy 1957 
15 LT Lithuania 2004 
16 NL Netherlands 1957 
17 NO Norway N/A 
18 PL Poland 2004 
19 PT Portugal 1986 
20 RO Romania 2007 
21 SE Sweden 1995 
22 SI Slovenia 2004 
23 SK Slovak Republic 2004 
24 UK United Kingdom 1973 
Notes: 
N/A = Not an EU member state 
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Appendix 4: Raw Data and Qualitative Codings for Fuzzy Sets 
Case 
PEN SUR PHE GNI O65 COO RPS 
Penetration 
2007 or 
latest (%) 
Qualitative 
Coding 
Survival 
rate 
until 
2008 (%) 
Qualitative 
Coding 
Public health 
expenditure (% 
of total health 
expenditure) 
2006 
GNI per 
capita 
(current 
US$) 
2007 or 
latest 
Population 
ages 65 and 
above (%) 
2007 
Coordination 
index or other 
source (see 
text) 
RPS 
since 
AT 18.7 0.4 N/A 0 75.9 41960 16.7 1 NA 
BE 10.2 0.2 25 0.2 72.5 41110 17.4 0.74 2001 
CH 11.3 0.2 40 0.4 59.1 60820 16.0 0.51 2002 
CZ 33.0 1 100 1 88.0 14580 14.6 CEE 1995 
DE 30.3 1 81 0.8 76.9 38990 19.6 0.95 1989 
DK 20.5 0.6 25 0.2 85.9 55440 15.6 0.7 1993 
ES 7.2 0 68 0.6 71.2 29290 17.0 0.57 2000 
FI 20.2 0.6 100 1 76.0 44300 16.3 0.72 2009 
FR 9.5 0 100 1 79.7 38810 16.3 0.69 2003 
GR 13.0 0.2 100 1 62.0 25740 18.5 Greece 2006 
HU 34.2 1 67 0.6 70.9 11680 15.5 CEE 1991 
IE 8.0 0 40 0.4 78.3 47610 11.1 0.29 NA 
IS 17.0 0.4 100 1 82.0 57750 12.0 Nordic 1995 
IT 20.3 0.6 88 0.8 77.2 33490 20.1 0.87 2001 
LT 41.6 1 N/A 0 70.0 9770 15.7 CEE 2003 
NL 19.2 0.4 50 0.4 80.0 45650 14.6 0.66 1991 
NO 13.9 0.2 N/A 0 83.6 77370 14.8 0.76 NA 
PL 61.0 1 67 0.6 70.0 9850 13.3 CEE 1998 
PT 17.4 0.4 90 0.8 70.5 18950 17.1 0.72 2003 
RO 28.5 0.8 33 0.2 76.9 6390 14.9 CEE Yes 
SE 14.5 0.2 100 1 81.7 47870 17.6 0.69 NA 
SI 32.6 1 33 0.2 72.2 21510 16.0 CEE 2003 
SK 44.6 1 N/A 0 70.6 11720 11.9 CEE 1995 
UK 29.1 0.8 50 0.4 87.3 40660 16.2 0.07 NA 
 
